var title_f36_57_37776="Lidocaine: Pediatric drug information";
var content_f36_57_37776=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lidocaine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/59/30642?source=see_link\">",
"       Lidocaine (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/11/20663?source=see_link\">",
"       Lidocaine (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/50/33574?source=see_link\">",
"       Lidocaine (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12551 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-3A7D25EF8E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_57_37776=[""].join("\n");
var outline_f36_57_37776=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/59/30642?source=related_link\">",
"      Lidocaine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/11/20663?source=related_link\">",
"      Lidocaine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/50/33574?source=related_link\">",
"      Lidocaine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_57_37777="Pyoderma gangrenosum";
var content_f36_57_37777=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pyoderma gangrenosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peristomal pyoderma gangrenosum is caused by an inflammatory process that produces severe and painful skin ulcerations; while these lesions most commonly occur on the legs, they are also seen in the peristomal area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dorothy B Doughty, MN, RN, CWOCN, FAAN.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_57_37777=[""].join("\n");
var outline_f36_57_37777=null;
var title_f36_57_37778="Patient information: Steroid medicines (The Basics)";
var content_f36_57_37778=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83983\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/1/30748\">",
"         Some examples of steroid medicines",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/30/483\">",
"         Patient information: Dealing with side effects from medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/43/37554\">",
"         Patient information: Medicine brand and generic names (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/61/32726\">",
"         Patient information: Reducing the costs of medicines (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Steroid medicines (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/steroid-medicines-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H26050810\">",
"      <span class=\"h1\">",
"       What are steroid medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Steroid medicines are a group of medicines that can treat many different medical conditions. These medicines are not the same steroids that athletes take to build muscle. Steroid medicines are a man-made form of a hormone the body makes naturally. This hormone is called &ldquo;cortisol.&rdquo; Doctors and nurses call steroid medicines &ldquo;glucocorticoids.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26050825\">",
"      <span class=\"h1\">",
"       What do steroid medicines do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Steroid medicines work in a few different ways. They can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Reduce or control inflammation",
"        </strong>",
"        &ndash; Many different medical conditions and some injuries cause swelling or inflammation. Depending on which body part is affected, the inflammation can cause pain or other symptoms, such as trouble breathing. Steroid medicines reduce or prevent that inflammation. That&rsquo;s why steroid medicines can help with conditions that cause inflammation, such as eczema and asthma. &nbsp;",
"       </li>",
"       <li>",
"        <strong>",
"         Reduce autoimmune responses",
"        </strong>",
"        &ndash; Some medical conditions happen when the body&rsquo;s infection-fighting system, called the &ldquo;immune system,&rdquo; attacks healthy cells. This is called an &ldquo;autoimmune response.&rdquo; Steroid medicines can help prevent this attack. That&rsquo;s why steroid medicines can help with autoimmune conditions such as lupus, rheumatoid arthritis, and multiple sclerosis.",
"       </li>",
"       <li>",
"        <strong>",
"         Replace hormones that are missing in the body",
"        </strong>",
"        &ndash; Some medical conditions happen when the body makes too little of the hormone cortisol. This hormone is important, because it controls how the body uses sugar (the body&rsquo;s main source of energy.) Steroid medicines replace the missing cortisol. That&rsquo;s why steroid medicines can help with conditions that affect how much cortisol the body makes, such as Addison&rsquo;s disease or congenital adrenal hyperplasia (also called CAH). &nbsp; &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Steroid medicines are an important part of treating many medical conditions. If you have a serious condition, they can even save your life. But steroids can also cause side effects. For example, they can cause weight gain, eye problems, or weak bones that are more likely to break. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26050839\">",
"      <span class=\"h1\">",
"       Which steroid medicines might I need?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are many different types of steroid medicines. Your doctor will decide which one is best for you. He or she will give you the lowest dose for the shortest possible time. This lowers the risk of side effects or makes them less severe.",
"     </p>",
"     <p>",
"      If you need steroid medicines for months or years, you will have regular exams and tests. Your doctor will check for steroid side effects and treat them if they happen. &nbsp;",
"     </p>",
"     <p>",
"      The list below gives some basic information on steroid medicines. The table lists the names of some commonly used steroid medicines (",
"      <a class=\"graphic graphic_table graphicRef83858 \" href=\"mobipreview.htm?30/1/30748\">",
"       table 1",
"      </a>",
"      ). For more detailed information about your medicines, ask your doctor or nurse for information from Lexicomp available through UpToDate. The Lexicomp handouts explain how to use and store your medicines. They also list possible side effects and warn you if your medicines should not be taken with certain other medicines or foods.",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Oral steroid medicines",
"        </strong>",
"        &ndash;",
"        <strong>",
"        </strong>",
"        Oral steroids come in pills or liquids you take by mouth. You usually take these in the morning. That&rsquo;s because your body&rsquo;s natural cortisol is highest in the morning. Taking oral steroids in the morning keeps your body closer to its natural hormone pattern. It also makes it less likely that the medicine will keep you awake at night.",
"        <br/>",
"        <br/>",
"        If and when you stop taking oral steroids, do it with the help of your doctor or nurse. He or she will tell you how to lower the dose slowly over time. Stopping oral steroids suddenly can cause bothersome symptoms. It can even be dangerous.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Inhaled steroid medicines",
"        </strong>",
"        &ndash;",
"        <strong>",
"        </strong>",
"        Inhaled steroids come in a device called an &ldquo;inhaler&rdquo; that helps you breathe in the medicine. This is a common treatment for asthma.",
"       </li>",
"       <li>",
"        <strong>",
"         Topical steroid medicines",
"        </strong>",
"        &ndash;",
"        <strong>",
"        </strong>",
"        Topical steroids are in lotions, ointments, gels, and creams you put on your skin.",
"       </li>",
"       <li>",
"        <strong>",
"         Steroid drops or sprays that go in your eyes, ears, or nose",
"        </strong>",
"        -",
"        <strong>",
"        </strong>",
"        Doctors sometimes prescribe steroids to reduce inflammation in your eyes, ears, or nose.",
"       </li>",
"       <li>",
"        <strong>",
"         Steroid injections",
"        </strong>",
"        &ndash;",
"        <strong>",
"        </strong>",
"        Doctors sometimes inject steroid medicines directly into a joint, the spine, or another part of the body. This can reduce pain, inflammation, and other problems.",
"        <br/>",
"        <br/>",
"        Doctors can also give steroid medicines at the hospital. These medicines are given through a thin tube called an &ldquo;IV&rdquo; that goes into a vein.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26050854\">",
"      <span class=\"h1\">",
"       What side effects can steroid medicines cause?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The side effects are different depending on what form of steroids you take (such as oral, inhaled, or other). Also, the medicines do not always cause side effects. Side effects are most likely if you use steroids for a long time or at high doses.",
"     </p>",
"     <p>",
"      The most common side effects of oral steroids include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Weight gain",
"       </li>",
"       <li>",
"        Changes in mood and thinking &nbsp;",
"       </li>",
"       <li>",
"        Trouble sleeping",
"       </li>",
"       <li>",
"        Thin skin",
"       </li>",
"       <li>",
"        Eye problems",
"       </li>",
"       <li>",
"        Heart problems",
"       </li>",
"       <li>",
"        Osteoporosis and other bone problems",
"       </li>",
"       <li>",
"        Growth problems in children",
"       </li>",
"       <li>",
"        High blood sugar",
"       </li>",
"       <li>",
"        Higher chance of getting infections &nbsp;",
"        <br/>",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you take steroid medicines for a long time, you need regular exams and tests. Your doctor or nurse will check for side effects and treat them if they happen.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26050871\">",
"      <span class=\"h1\">",
"       What else should I know about steroid medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Always take steroid medicines exactly the way your doctor or nurse tells you. This helps the medicines work better and can help reduce side effects. For example, if your doctor prescribes a steroid cream, only use it as often as the prescription says. If you take an inhaled steroid, make sure you know how to use the inhaler correctly. Keep using it as the prescription says, even if you do not feel the medicine working. For any steroid medicine, ask your doctor for instructions and make sure you understand them. Call your doctor or nurse if you have any questions.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26050888\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/30/483?source=see_link\">",
"       Patient information: Dealing with side effects from medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/43/37554?source=see_link\">",
"       Patient information: Medicine brand and generic names (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       Patient information: Reducing the costs of medicines (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/57/37778?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83983 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A392849A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_57_37778=[""].join("\n");
var outline_f36_57_37778=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26050810\">",
"      What are steroid medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26050825\">",
"      What do steroid medicines do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26050839\">",
"      Which steroid medicines might I need?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26050854\">",
"      What side effects can steroid medicines cause?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26050871\">",
"      What else should I know about steroid medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26050888\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83983\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/1/30748\">",
"      Some examples of steroid medicines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/43/37554?source=related_link\">",
"      Patient information: Medicine brand and generic names (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_57_37779="Iodinated radiocontrast agents in the treatment of hyperthyroidism";
var content_f36_57_37779=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Iodinated radiocontrast agents in the treatment of hyperthyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/57/37779/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/57/37779/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/57/37779/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/57/37779/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/57/37779/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/57/37779/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/57/37779/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of this writing, neither iopanoic acid nor ipodate are available in the United States. It is unclear when, or even whether, they will ever again be marketed in the United States.",
"   </p>",
"   <p>",
"    Ipodate and iopanoic acid, two oral iodine-containing drugs marketed as oral cholecystographic agents, have been used in the treatment of hyperthyroidism. These drugs are the most potent inhibitors of 5'-monodeiodinase, thereby impairing the extrathyroidal conversion of thyroxine (T4) to the more potent triiodothyronine (T3). The release of iodine in pharmacologic quantities from these agents has the additional benefits of blocking thyroid hormone release and interfering with its synthesis in some patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10852?source=see_link\">",
"     \"Iodine in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These agents are more potent than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/9/5271?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    in blocking the conversion of T4 to T3, and they result in a rapid reduction in serum T4 and T3 concentrations (",
"    <a class=\"graphic graphic_figure graphicRef54848 \" href=\"mobipreview.htm?1/1/1054\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37779/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Doses in most studies have ranged from 500 mg to 1000 mg as a single daily dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LIMITATIONS TO USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ipodate and iopanoic acid have been used as monotherapy for the treatment of hyperthyroidism caused by Graves' disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37779/abstract/3\">",
"     3",
"    </a>",
"    ]. However, they are not as effective as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/9/5271?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    in controlling the hyperthyroidism, and the relapse rate after therapy is discontinued is higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37779/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are also several additional problems with the use of these agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They may induce hyperthyroidism that is resistant to conventional doses of thionamides [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37779/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      They should not be used as monotherapy in patients with toxic adenoma or toxic multinodular goiter, since the iodine may provide substrate for de novo hormone synthesis by the autonomous thyroid tissue, leading to more severe hyperthyroidism. They can be used in this setting only if thyroid hormone synthesis is first blocked by the administration of a thionamide. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/30/41448?source=see_link\">",
"       \"Treatment of toxic adenoma and toxic multinodular goiter\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MAJOR USES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major use of the iodinated radiocontrast agents has been in the treatment of severe hyperthyroidism or \"thyroid storm.\" The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    and ipodate in such patients is more effective than methimazole alone or methimazole plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    , and the serum T3 concentration may fall to normal within five days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37779/abstract/6\">",
"     6",
"    </a>",
"    ]. This rapid effect can also be used to quickly prepare patients for thyroid surgery.",
"   </p>",
"   <p>",
"    Patients with Graves' hyperthyroidism who require rapid preparation for surgery or who are allergic to thionamides and who choose surgery also can benefit from an iodinated radiocontrast agent. These patients can be rendered euthyroid within five days with the triad of the radiocontrast agent, a &szlig;-blocker, and a glucocorticoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37779/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. As noted above, long-term use of these agents may result in resistant hyperthyroidism and should therefore be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37779/abstract/5\">",
"     5",
"    </a>",
"    ]. Iopanoic acid has also helped to lower T3 levels and hyperthyroid symptoms preoperatively in patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    associated hyperthyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37779/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These agents may also be effective during the hyperthyroid phase that can occur with subacute thyroiditis, a disorder in which thionamides are of no benefit since thyroid hormone is leaking from an inflamed gland. As an example, serum T3 levels fell rapidly after ipodate administration (500 mg daily or every other day) and patients noted symptomatic improvement within several days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37779/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Ipodate was continued for 15 to 60 days until both T3 and T4 levels normalized.",
"   </p>",
"   <p>",
"    Ipodate or iopanoic acid also may be useful in both adults and children with an acute",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    overdose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37779/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Iopanoic acid, 500 mg daily for seven days, rapidly ameliorates Graves' hyperthyroidism. Sufficient recovery of the radioiodine uptake to allow radioiodine treatment occurs after one or two weeks after stopping iopanoic acid in 86 and 94 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37779/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, neither iopanoate nor ipodate are available in the United States. It is unclear when, or even whether, they will ever again be marketed in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/9/22674?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/6/3172?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/15/23794?source=see_link\">",
"       \"Patient information: Antithyroid drugs (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ipodate and iopanoic acid impair the extrathyroidal conversion of thyroxine (T4) to the more potent triiodothyronine (T3). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      They should not be used as monotherapy in patients with Graves' hyperthyroidism, toxic adenoma, or toxic multinodular goiter since the iodine may provide substrate for de novo hormone synthesis by the autonomous thyroid tissue, leading to more severe hyperthyroidism. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Limitations to use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In countries where these agents are available, they can be used in conjunction with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"       methimazole",
"      </a>",
"      for the treatment of severe hyperthyroidism or \"thyroid storm.\" In patients with Graves' hyperthyroidism who are allergic to thionamides and who choose surgery, the combination of an iodinated radiocontrast agent, a &szlig;-blocker, and a glucocorticoid can be used to normalize thyroid tests prior to surgery. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Major uses'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37779/abstract/1\">",
"      Wu SY, Shyh TP, Chopra IJ, et al. Comparison sodium ipodate (oragrafin) and propylthiouracil in early treatment of hyperthyroidism. J Clin Endocrinol Metab 1982; 54:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37779/abstract/2\">",
"      Robuschi G, Manfredi A, Salvi M, et al. Effect of sodium ipodate and iodide on free T4 and free T3 concentrations in patients with Graves' disease. J Endocrinol Invest 1986; 9:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37779/abstract/3\">",
"      Shen DC, Wu SY, Chopra IJ, et al. Long term treatment of Graves' hyperthyroidism with sodium ipodate. J Clin Endocrinol Metab 1985; 61:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37779/abstract/4\">",
"      Martino E, Balzano S, Bartalena L, et al. Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism. J Endocrinol Invest 1991; 14:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37779/abstract/5\">",
"      Caldwell G, Errington M, Toft AD. Resistant hyperthyroidism induced by sodium iopodate used as treatment for Graves' disease. Acta Endocrinol (Copenh) 1989; 120:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37779/abstract/6\">",
"      Roti E, Robuschi G, Gardini E, et al. Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves' disease. Clin Endocrinol (Oxf) 1988; 28:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37779/abstract/7\">",
"      Baeza A, Aguayo J, Barria M, Pineda G. Rapid preoperative preparation in hyperthyroidism. Clin Endocrinol (Oxf) 1991; 35:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37779/abstract/8\">",
"      Panzer C, Beazley R, Braverman L. Rapid preoperative preparation for severe hyperthyroid Graves' disease. J Clin Endocrinol Metab 2004; 89:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37779/abstract/9\">",
"      Bogazzi F, Miccoli P, Berti P, et al. Preparation with iopanoic acid rapidly controls thyrotoxicosis in patients with amiodarone-induced thyrotoxicosis before thyroidectomy. Surgery 2002; 132:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37779/abstract/10\">",
"      Chopra IJ, van Herle AJ, Korenman SG, et al. Use of sodium ipodate in management of hyperthyroidism in subacute thyroiditis. J Clin Endocrinol Metab 1995; 80:2178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37779/abstract/11\">",
"      Arem R, Munipalli B. Ipodate therapy in patients with severe destruction-induced thyrotoxicosis. Arch Intern Med 1996; 156:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37779/abstract/12\">",
"      Berkner PD, Starkman H, Person N. Acute L-thyroxine overdose; therapy with sodium ipodate: evaluation of clinical and physiologic parameters. J Emerg Med 1991; 9:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37779/abstract/13\">",
"      Brown RS, Cohen JH 3rd, Braverman LE. Successful treatment of massive acute thyroid hormone poisoning with iopanoic acid. J Pediatr 1998; 132:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37779/abstract/14\">",
"      Braga M, Cooper DS. Clinical review 129: Oral cholecystographic agents and the thyroid. J Clin Endocrinol Metab 2001; 86:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37779/abstract/15\">",
"      Bal CS, Kumar A, Chandra P. Effect of iopanoic acid on radioiodine therapy of hyperthyroidism: long-term outcome of a randomized controlled trial. J Clin Endocrinol Metab 2005; 90:6536.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7877 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-79.122.249.114-3C057D9C1B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_57_37779=[""].join("\n");
var outline_f36_57_37779=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LIMITATIONS TO USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MAJOR USES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7877\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7877|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/1/1054\" title=\"figure 1\">",
"      Ipodate versus PTU hyperthyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10852?source=related_link\">",
"      Iodine in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/15/23794?source=related_link\">",
"      Patient information: Antithyroid drugs (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/9/22674?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/30/41448?source=related_link\">",
"      Treatment of toxic adenoma and toxic multinodular goiter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_57_37780="Zafirlukast: Patient drug information";
var content_f36_57_37780=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Zafirlukast: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"     see \"Zafirlukast: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/22/41316?source=see_link\">",
"     see \"Zafirlukast: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Accolate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F235422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Accolate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691494",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat asthma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703138",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to zafirlukast or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703781",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is",
"       <b>",
"        not",
"       </b>",
"       helpful during an asthma attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to get the breathing attack under control.",
"       <b>",
"        Get help right away.",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698663",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in the way you act.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take even during sign-free periods.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699399",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in the original container at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11149 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-217.117.136.88-353D9881C8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_57_37780=[""].join("\n");
var outline_f36_57_37780=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235421\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235422\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028575\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028574\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028579\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028580\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028582\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028577\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028578\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028583\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028584\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=related_link\">",
"      Zafirlukast: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/22/41316?source=related_link\">",
"      Zafirlukast: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_57_37781="Manual intraosseous needle placement";
var content_f36_57_37781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Manual intraosseous needle placement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 654px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The needle is angled slightly away from the joint space or, as some more recent sources have recommended, perpendicular to the bone.",
"    <br>",
"     (B) A back-and-forth \"screwing\" motion is used to insert the needle. \"Rocking\" the needle from side to side results in enlargement of the puncture site and extravasation of infused fluid.",
"     <br>",
"      (C) Intramedullary placement is confirmed by aspirating marrow.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Hodge D III. Intraosseous infusion. In: Textbook of Pediatric Emergency Procedures, 2nd Edition, King C, Henretig FM, Eds. Lippincott Williams &amp; Wilkins, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"      </div>",
"      <div class=\"contractual\">",
"       <br/>",
"       <a href=\"file://www.lww.com\">",
"        file://www.lww.com",
"       </a>",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_57_37781=[""].join("\n");
var outline_f36_57_37781=null;
var title_f36_57_37782="Pararenal abdominal aortic aneurysm";
var content_f36_57_37782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Pararenal abdominal aortic aneurysm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large 6 by 5.4 cm pararenal AAA can be&nbsp;seen in the coronal CT&nbsp;reconstruction (A) encroaching on the&nbsp;right renal artery (arrow). In the cross sectional images, the right renal artery (arrow in B) and&nbsp;the left renal artery (arrow in C) can be seen.",
"    <div class=\"footnotes\">",
"     AAA: abdominal aortic aneurysm; CT: computed tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_57_37782=[""].join("\n");
var outline_f36_57_37782=null;
var title_f36_57_37783="DLBCL immunoblast variant";
var content_f36_57_37783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Immunoblast variant of diffuse large B-cell lymphoma in a lymph node biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tumor cells show large vesicular nuclei with single prominent nucleolus and moderate amount of cytoplasm. Hematoxylin and eosin, 100x magnification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Clinical application, case 32 diffuse large B-cell lymphoma. In: Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_57_37783=[""].join("\n");
var outline_f36_57_37783=null;
var title_f36_57_37784="Lupus panniculitis facial lipoatrophy";
var content_f36_57_37784=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85711%7EDERM%2F85712%7EDERM%2F83791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85711%7EDERM%2F85712%7EDERM%2F83791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lupus panniculitis (lupus profundus)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lipoatrophy is present on the face of this patient with lupus panniculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Lupus panniculitis (lupus profundus)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lipoatrophy, discoid lupus-like changes, and inflammatory nodules are present on the upper extremities in this patient with lupus panniculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lupus panniculitis (lupus profundus)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous nodules (chest and abdomen) and lipoatrophy (upper arm) in lupus panniculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Scott Crater, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_57_37784=[""].join("\n");
var outline_f36_57_37784=null;
var title_f36_57_37785="Intermediate- and long-term mechanical cardiac support";
var content_f36_57_37785=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intermediate- and long-term mechanical cardiac support",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/57/37785/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/57/37785/contributors\">",
"     Emma Jane Birks, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/57/37785/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/57/37785/contributors\">",
"     Donna Mancini, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/57/37785/contributors\">",
"     Sharon A Hunt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/57/37785/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/57/37785/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/57/37785/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H23100009\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical therapy (including angiotensin converting enzyme inhibitors, beta blockers, and aldosterone antagonists), cardiac resynchronization therapy, and implantable cardioverter-defibrillators have improved the survival of many with heart failure, but there remains a large group of patients who have advanced heart failure with poor prognosis despite optimal medical therapy. Unfortunately, the numbers of useable donor hearts available to perform heart transplantation for these patients has not increased in the US and has actually decreased in Europe over recent years and the supply is and will remain inadequate for the population who could benefit from heart transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mechanical support of the circulation with left ventricular assist devices (LVADs) is a rapidly evolving field. LVADs are efficient devices that assist and support the circulation and they are being inserted into an increasing number of patients with advanced heart failure. Mechanical circulatory support with a ventricular assist device (VAD) is a life-saving therapy for patients with decompensating advanced heart failure who fail to improve or stabilize with optimal medical therapy.",
"   </p>",
"   <p>",
"    This topic will discuss intermediate- and long-term VAD therapy. Short-term mechanical support is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15911?source=see_link\">",
"     \"Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22787795\">",
"    <span class=\"h1\">",
"     CATEGORIES OF USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A VAD can be used as a bridge to cardiac transplantation (to sustain life until a donor heart becomes available), as a bridge to decision (regarding transplant eligibility), as destination (or permanent) therapy, or as a bridge to recovery of heart function. Most patients receiving mechanical cardiac support for these indications receive a left ventricular assist device (LVAD) with less than 15 percent receiving biventricular support in the form of biventricular device (BiVAD) (left plus right ventricular support) or total artificial heart (TAH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22787804\">",
"    <span class=\"h2\">",
"     Bridge to transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermediate- or long-term left ventricular assist devices (LVADs) can be used as bridges to transplantation (BTT) in patients with advanced heart failure with deteriorating clinical status who are or may be candidates for heart transplantation but are&nbsp;too unstable to wait any longer without circulatory support. LVADs are inserted into patients who have worsening New York Heart Association (NYHA) Class IV heart failure (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) despite inotropic plus intraaortic balloon pump support. Such patients often also have end organ dysfunction or other potentially reversible medical conditions that may be temporary contraindications to cardiac transplantation (for which LVAD use may be considered a &ldquo;bridge to candidacy&rdquo; or &ldquo;bridge to decision&rdquo;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/2\">",
"     2",
"    </a>",
"    ]. Not only are LVADs life-saving in these deteriorating patients who might otherwise die before a donor heart becomes available, but they can also improve secondary organ function prior to transplantation, reduce pulmonary hypertension, and enable improvement in nutritional status, all of which are associated with improved post-transplant survival.",
"   </p>",
"   <p>",
"    Due to the stagnant numbers of donor hearts, an increasing number of patients have been requiring LVAD support for survival prior to transplantation. The International Society of Heart and Lung Transplantation (ISHLT) 2010 report documented that pre-transplant support with intravenous inotropes decreased from 55.3 to 44.5 percent while LVAD therapy has increased from 13.4 to 20.1 percent over the last two decades (1992 to 2001 versus 2002 to",
"    <span class=\"nowrap\">",
"     2006/2009)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/3\">",
"     3",
"    </a>",
"    ]. The survival of status I patients continues to depend on urgent cardiac replacement therapy with 52.4 percent of patients listed between 2000 and 2005 dying within six months without heart transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/4\">",
"     4",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H599696\">",
"    <span class=\"h2\">",
"     Bridge to decision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients receive an LVAD before a final decision regarding transplantation eligibility has been able to be reached (use of which has been termed &ldquo;bridge to decision&rdquo; or BTD). This is because many patients on inotropic agents or intraaortic balloon pump support have secondary end organ dysfunction or other potentially reversible medical conditions, which may be temporary contraindications to cardiac transplantation. For them, mechanical support may be able to reverse the contraindication. Forty-two percent of LVADs in the INTERMACS database implanted from June 2006 to June 2010 were inserted as a BTD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/5\">",
"     5",
"    </a>",
"    ], attesting to the frequency of VAD use for this reason.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22787811\">",
"    <span class=\"h2\">",
"     Destination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As survival rates with LVAD support have improved, the use of these devices as permanent (rather than &ldquo;bridge&rdquo; therapy) has evolved and expanded considerably [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/5\">",
"     5",
"    </a>",
"    ]. Destination therapy (DT) refers to this long-term use of LVADs as an alternative to transplantation in candidates in patients with end stage heart failure who are considered to be ineligible for transplantation. Improvements in VAD devices have made such destination therapy a realistic option for these patients. The current generation of LVADs are more durable than their predecessors and have lower complication rates, particularly low rates of device failure; hence, patients can be maintained on them for much longer periods of time with lower morbidity, making destination therapy now a realistic option for many patients.",
"   </p>",
"   <p>",
"    There are now 101 centers in the US that have been designated DT centers by the Centers for Medicare and Medicaid Services (CMS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/5\">",
"     5",
"    </a>",
"    ]. In the US, there has been a doubling of the proportion of implants for DT as a primary indication from 16 percent in 2006 to 34 percent in 2011 and the proportion implanted for bridge to transplantation (BTT) has decreased from 44 to 23 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/5\">",
"     5",
"    </a>",
"    ]. A report from the INTERMACS database on 2506 primary adult LVADs implanted between June 2006 and September 2010 showed that the most common contraindications to transplantation in DT patients were advanced age, renal dysfunction, high body mass index (BMI), pulmonary hypertension, and other comorbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/5\">",
"     5",
"    </a>",
"    ]. There is some cross-over, with nearly 10 percent of patients implanted designated as DT subsequently undergoing transplantation by 12 months after LVAD implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/5\">",
"     5",
"    </a>",
"    ]. In many patients, this is due to unexpected recovery of end organ damage although in some the crossover to transplant is due to device complications such as inability to cure a device infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The various causes of death after LVAD implantation for DT reflect associated co-morbidities and the generally limited reserve of these patients who are ineligible for cardiac transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/5\">",
"     5",
"    </a>",
"    ]. An Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) report on 385 patients identified risk factors for early death which included critical cardiogenic shock, elevated blood urea nitrogen (BUN), need for concomitant surgery, and need for biventricular assist device (Bi-VAD) support (",
"    <a class=\"graphic graphic_table graphicRef85809 \" href=\"mobipreview.htm?0/29/477\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/5\">",
"     5",
"    </a>",
"    ]. Risk factors for death throughout the implantation period were older age, diabetes, pulmonary hypertension, hyponatremia, and pulsatile flow (older generation) LVAD support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22787818\">",
"    <span class=\"h2\">",
"     Bridge to recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is now compelling evidence that LVAD unloading can promote recovery of myocardial function. This recovery can be sufficient to allow device removal without cardiac transplantation and leave the patient with an excellent quality of life. When this occurs, the precious resource of a donor organ can be used for another needy individual. The strategy of device implantation to promote recovery of myocardial function is known as &ldquo;bridge to recovery&rdquo; (BTR). Many cases of successful VAD bridge to recovery have been described in patients with acute myocarditis, but there is a growing literature regarding recovery in patients with chronic dilated cardiomyopathy.",
"   </p>",
"   <p>",
"    In the major published studies addressing the issue of myocardial recovery with VAD support in patients with dilated cardiomyopathy, a strategy that combined mechanical unloading using LVAD support with specific pharmacologic interventions to maximize the incidence of myocardial recovery and to improve the durability of recovery following explantation resulted in much higher VAD explantation rates than had previously been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The pharmacologic interventions of the first phase of the therapy (including ACE inhibitors [or angiotensin II receptor blockers], beta blockers, and aldosterone antagonists), were designed to reverse pathological hypertrophy and remodeling and to normalize cellular metabolic function. These pharmacologic agents were given at very high doses, doses that these patients would not have tolerated before pump insertion because of hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal dysfunction. The underling cardiac function was regularly measured throughout the process with the pump off, or for a continuous flow pump, with the speed reduced to a point at which it was not producing any net forward flow. When maximal reverse remodeling, as judged by echocardiographic measurements of left ventricular dimensions with the pump switched off (under full heparinization) was felt to have been achieved, clenbuterol was given as the second phase. This drug is an anabolic steroid that has been shown to induce physiologic hypertrophy in several experimental models including those with pressure overload hypertrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myocardial recovery in patients on an LVAD provides an ideal and so far unique opportunity to study the molecular mechanisms that occur during reverse remodeling as the patient recovers. Myocardial samples obtained at the time of device insertion and later removal, along with serum samples, provide an ideal opportunity to explore the myocardial and circulating factors involved in the recovery of human heart failure. &nbsp;",
"   </p>",
"   <p>",
"    VADs may well be used as a platform to induce myocardial recovery by combining with other therapies, such as stem cells, in the future. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18617?source=see_link\">",
"     \"Genetic and cellular therapy in heart failure and myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H601056\">",
"    <span class=\"h1\">",
"     DEVICE OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;LVADs have evolved over the years and are still rapidly evolving. They can broadly be divided into first, second, and third generation devices according to their mechanism of operation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H601048\">",
"    <span class=\"h1\">",
"     FIRST GENERATION DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first generation of ventricular assist devices were the pulsatile positive displacement pumps, which include the HeartMate I, the Thoratec Paracorporeal Ventricular Assist Device (PVAD), and the Novacor. These pulsatile volume-displacement devices provide excellent hemodynamic support and improved survival but have limitations, particularly limited long-term device durability, the need for extensive surgical dissection to implant, the presence of a large external lead (which is more prone to infection), an audible pump, and the need for medium-large body habitus. Hence, although most early published studies of LVADs involved these devices, only the Thoratec Paracorporeal Ventricular Assist Device is commercially available and it is rarely used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22787832\">",
"    <span class=\"h2\">",
"     HeartMate I device",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HeartMate I (HM I) was inserted in over 5000 patients. It has a pusher-plate actuator that is powered pneumatically or electrically. A cannula is placed in the apex of the left ventricle and blood flows through a Dacron conduit through a porcine valve to the pump and is returned into a Dacron outflow graft through another porcine valve inserted in the ascending aorta. The HeartMate I contains a unique blood pumping surface consisting of titanium microspheres and a fibrillar textured inner surface that promoted the formation of a &ldquo;pseudointima&rdquo; that resists thrombogenesis. Thus, the only antithrombotic therapy needed was",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . &nbsp;",
"   </p>",
"   <p>",
"    The HeartMate I underwent several design improvements and evolved from the pneumatic to the vented electric (VE) to the XVE (",
"    <a class=\"graphic graphic_figure graphicRef86141 \" href=\"mobipreview.htm?41/11/42165\">",
"     figure 1",
"    </a>",
"    ). However, the excellent results and better durability with the second and third generation devices have made its use obsolete and it is no longer in production. However, it was this device that was used in the landmark REMATCH trial (discussed below), which became the basis for approval of destination therapy. (See",
"    <a class=\"local\" href=\"#H601173\">",
"     'As destination therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22787839\">",
"    <span class=\"h2\">",
"     Thoratec paracorporeal ventricular assist device (PVAD)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Thoratec paracorporeal ventricular assist device (PVAD) has been inserted in over 3000 patients. It has a 65 mL stroke volume pumping chamber and two mechanical valves. It has the advantage that it can be used as an LVAD, RVAD, or two together as a BIVAD. Alternating positive and negative air pressure generated by a console or portable pneumatic driver produces a beat rate of 40 to 110 bpm and a flow rate of 1.3 to 7.2",
"    <span class=\"nowrap\">",
"     L/min.",
"    </span>",
"    The PVAD is positioned outside the body (paracorporeal) on the anterior abdominal wall with cannulas crossing into the chest wall. Patients supported by this pump require",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (goal INR 2.5 to 3.5) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy. The IVAD is an implantable version of this pump.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22787846\">",
"    <span class=\"h2\">",
"     Novacor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Novacor LVAD was implanted in over 1600 patients for durations of up to 6.1 years, but has been discontinued after trials showing a high rate of stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22787853\">",
"    <span class=\"h1\">",
"     SECOND GENERATION DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been a dramatic shift from use of the first generation pulsatile pumps to use of the second generation devices which are continuous (non-pulsatile) axial or centrifugal flow pump devices . INTERMACS records show an increase in the use of continuous flow pumps from none implanted in 2007 to 1445 implanted in 2010 while use of pulsatile intracorporeal pumps decreased from 219 in 2007 to only six in 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/5\">",
"     5",
"    </a>",
"    ]. By the first half of 2007, more than 99 percent of US Food and Drug Administration (FDA)-approved LVAD implants were continuous flow devices (",
"    <a class=\"graphic graphic_figure graphicRef86142 \" href=\"mobipreview.htm?9/7/9333\">",
"     figure 2",
"    </a>",
"    ). Unlike the first generation devices, these continuous flow pumps have only one moving part, the rotor, and hence are much more durable. They are also smaller (principally through elimination of the blood sac or reservoir necessary for a pulsatile system), quieter, and hence surgical implantation is generally less traumatic. Continuous flow pumps also have smaller drivelines and hence tend to have lower rates of driveline infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22787860\">",
"    <span class=\"h2\">",
"     HeartMate II",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HeartMate II (HM II) device is a continuous flow axial blood pump (",
"    <a class=\"graphic graphic_figure graphicRef86142 \" href=\"mobipreview.htm?9/7/9333\">",
"     figure 2",
"    </a>",
"    ) with an internal rotor with helical blades that curve around a central shaft. As the blood flows around the pump rotor, the spinning action of the rotor, with its three curving blades, introduces a radial or tangential velocity to the blood flow as it imparts kinetic energy to the blood, which then flows past the outlet stator vanes. The twisted shape of the outlet stator vanes converts the radial velocity of the blood flow to an axial direction. The pump weighs 350 g and it is approximately 7 cm in length and 4 cm at its largest diameter. It can generate up to 10",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    of flow at a pressure of 100 mmHg. The axial flow design and absence of blood sac eliminates the need for venting of pulsatile volume (required for the first generation of implantable pumps), thus reducing the size of the percutaneous drive lead and also eliminating the need for internal one-way valves. Blood flows through an inflow cannula from the apex of the LV to the pump and returns back through an outflow cannula to the ascending aorta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22787867\">",
"    <span class=\"h2\">",
"     Jarvik 2000",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Jarvik 2000 is a continuous flow axial blood pump that has an intraventricular position, with the whole pump sitting within the LV cavity (",
"    <a class=\"graphic graphic_figure graphicRef86143 \" href=\"mobipreview.htm?22/37/23125\">",
"     figure 3",
"    </a>",
"    ). The pump weighs 85 g, measures 2.4 cm in diameter, and is 5.5 cm long. The single moving component is the impeller located in the center of the titanium housing. A brushless direct-current motor, contained within the housing, creates the electromagnetic force necessary to rotate the impeller. Blood flow is directed through the outlet graft by stator blades located near the pump outlet and it returns to either the ascending or descending aorta. The pump can generate up to a maximum of 7",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    of flow. Pump implantation with the outflow cannula in the descending aorta can result in stasis and clot formation in the aortic root; to avoid this, an intermittent low speed controller can be used that drops the pump speed for eight seconds every minute to allow the aortic valve to open. Additionally, anastomosis of the cannula to the ascending aorta rather than the descending aorta results in fewer static complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/11\">",
"     11",
"    </a>",
"    ]. Because this pump is not inserted in a pocket, serious pump infections are rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22787874\">",
"    <span class=\"h2\">",
"     Berlin Heart INCOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Berlin Heart INCOR is a continuous flow axial flow pump marketed in Europe but not in the US. As blood passes into the INCOR it first passes an inducer that directs laminar flow onto the impeller, which is suspended by a magnetic bearing and floats free of contact with other parts. The impeller operates at speeds between 5000 and 10,000 rotations per minute. Blood is then directed to a stationary diffuser that has specially aligned blades that reduce the rotational effect of the blood flow and thus builds additional pressure which assists in the transport of blood through the outflow cannula to the aorta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22787881\">",
"    <span class=\"h2\">",
"     MicroMed DeBakey",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MicroMed DeBakey VAD is another axial flow centrifugal pump marketed in Europe but not the US. It has an elbow&ndash;shaped inflow cannula that inserts into the LV apex, a pump housing unit that contains the impeller (which is actuated by an electromagnet), a Dacron outflow conduit graft, and an ultrasonic flow probe that encircles the outflow graft and provides direct online measurements of pump flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22787888\">",
"    <span class=\"h1\">",
"     THIRD GENERATION PUMPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Third generation VADs have been designed for long durability, compact size, optimization of blood flow through the device to minimize the risk of thrombus formation and hemolysis, and simplified surgical implantation. Although these third generation devices are just starting to be used, they are anticipated to last for 5 to 10 years. The HeartWare and DuraHeart devices are discussed here. Smaller versions of the third generation devices are currently in development and undergoing animal testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22787897\">",
"    <span class=\"h2\">",
"     HeartWare",
"    </span>",
"    &nbsp;&mdash;&nbsp;HeartWare (",
"    <a class=\"graphic graphic_figure graphicRef86144 \" href=\"mobipreview.htm?1/52/1859\">",
"     figure 4",
"    </a>",
"    ) is a continuous flow centrifugal third generation pump that is commercially available in Europe. In the US it was approved by the FDA as a bridge to transplantation in November 2012 and is being evaluated for clinical use as destination therapy in a clinical trial. HeartWare has only one moving part, the impeller, and no mechanical bearings. The pump weighs 140 g and has an external diameter of 53 mm. The impeller spins at rates between 1800 and 4000 rpm and generates up to 10",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    of blood flow. It is implantable directly adjacent to the heart in the pericardial space due to its small total size, equivalent to 50 cc. The impeller is suspended within the pump housing through a combination of passive magnets and a hydrodynamic thrust bearing.&nbsp;This hydrodynamic suspension is achieved by a gentle incline on the upper surfaces of the impeller blades. When the impeller spins, blood flows across these inclined surfaces, creating a \"cushion\" between the impeller and the pump housing. There is no contact between the impeller and the housing chamber. Device reliability is enhanced through the use of dual motor stators with independent drive circuitry, allowing a seamless transition between dual and single stator mode if required. The inflow cannula is integrated with the device itself, ensuring proximity between the heart and the pumping mechanism which facilitates implantation and ensures optimal blood flow characteristics.&nbsp;The impeller has a wide blade to help minimize risk of pump induced hemolysis or thrombus.",
"   </p>",
"   <p>",
"    Because the HeartWare pump has no bearings and runs at lower rpm, it is likely to have long durability. It is much smaller than earlier devices and easier to surgically implant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22787904\">",
"    <span class=\"h2\">",
"     DuraHeart",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DuraHeart device is commercially available in Europe and Japan and is under investigation in the US in bridge to transplantation trials. This device incorporates a centrifugal flow rotary pump with an active magnetically levitated impeller featuring three position sensors and magnetic coils that optimize blood flow, while minimizing device wear and tear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1787388\">",
"    <span class=\"h1\">",
"     BIVENTRICULAR SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candidates for biventricular mechanical support include those patients with severe biventricular failure or predominant right ventricular failure with significant left ventricular disease, patients with restrictive cardiomyopathies, or those with complex congenital heart disease and patients requiring re-transplantation.&nbsp;In patients who require long-term biventricular support, the device options are limited and include the Thoratec PVAD (intermediate durability only), the total artificial heart, and investigational compassionate use of HeartWare as biventricular support. (See",
"    <a class=\"local\" href=\"#H22787839\">",
"     'Thoratec paracorporeal ventricular assist device (PVAD)'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H22787897\">",
"     'HeartWare'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1787395\">",
"     'Total artificial heart'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1787395\">",
"    <span class=\"h2\">",
"     Total artificial heart",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SynCardia temporary Total Artificial Heart (TAH) device, originally developed 30 years ago as the Jarvik Total Artificial Heart and later renamed the CardioWest TAH, is a pulsatile total artificial heart that continues to be used clinically in over 50 centers worldwide. The SynCardia TAH is the only TAH system to receive FDA, CE, and Canadian Health approval for clinical implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/12\">",
"     12",
"    </a>",
"    ]. The size of the artificial heart has restricted its use to patients with a large enough body habitus to accommodate positioning within the thoracic cavity. To be eligible for use of the SynCardia TAH, the patients must have a body-surface area of &gt;1.7 or a distance of &ge;10 cm from the 10",
"    <sup>",
"     th",
"    </sup>",
"    anterior vertebral body to the inner table of the sternum on computed tomographic scanning (CT).",
"   </p>",
"   <p>",
"    The SynCardia TAH weighs 160 g and consists of two artificial ventricles, each made of semi-rigid polyurethane housing with four flexible polyurethane diaphragms separating the blood chambers from the air chambers (",
"    <a class=\"graphic graphic_figure graphicRef86145 \" href=\"mobipreview.htm?4/3/4146\">",
"     figure 5",
"    </a>",
"    ). The diaphragms enable the artificial ventricle to fill and then eject blood when compressed by air from the external console. Mechanical valves, mounted in the inflow (27 mm) and outflow (25 mm) ports of each artificial ventricle, control the direction of blood flow. The maximum dynamic stroke volume of each ventricle is 70 mL, which enables generation of a flow rate up to 9.5 L per minute. The left artificial ventricle is connected via the left atrial inflow connector to the left atrium, and via the aortic outflow cannula to the aorta. The right artificial ventricle is connected via the right atrial inflow connector to the right atrium and via the pulmonary artery outflow cannula to the pulmonary artery. Each artificial ventricle driveline conduit is tunneled through the chest wall. The right and left artificial ventricles are attached to seven-foot pneumatic drivelines that connect to the back of the external console. The external console weighs 180 kg and includes a monitoring computer that provides noninvasive diagnostic and monitoring information to the user, including device rates, dynamic stroke volumes, calculated cardiac outputs, drive pressure, flow waveforms, and trending information. Device status and patient related alarms (eg, low cardiac output) are also displayed on the console. Large SynCardia implant drivers are approved for use in the US, Canada, and Europe. A new portable console weighing 5.5 kg has received CE approval and is undergoing clinical trials for FDA approval. The SynCardia TAH was first implanted in a patient at the University of Arizona in 1988, and over 1100 patients have now been supported by the SynCardia TAH with the longest patient support being 1374 days prior to successful heart transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14205254\">",
"    <span class=\"h1\">",
"     CLINICAL USE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164479067\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular assist device (VAD) therapy is indicated in the following clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend left ventricular assist device (LVAD) therapy as a bridge to transplantation for selected patients with refractory heart failure due left ventricular dysfunction despite optimal pharmacologic and device treatment who are otherwise eligible for heart transplantation and for whom a donor heart is not readily available. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34297?source=see_link\">",
"       \"Indications and contraindications for cardiac transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In addition, we suggest an LVAD as a bridge to a decision regarding heart transplantation or VAD destination therapy eligibility in selected patients with refractory heart failure and hemodynamic instability",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      compromised end-organ function, with relative contraindications to heart transplantation who could improve with time or with the improved hemodynamics that the VAD will provide. In this clinical setting, support from a device may allow renal function, nutritional status, and pulmonary vascular resistance to improve over several weeks or months prior to subsequent transplantation. Transplantation should be considered in such patients only after these improvements have occurred.",
"     </li>",
"     <li>",
"      We recommend an LVAD as destination (or permanent) therapy in selected patients with refractory heart failure despite optimal pharmacologic, and device treatment and expert heart failure care who are not candidates for heart transplantation.",
"     </li>",
"     <li>",
"      We suggest implantation of biventricular mechanical (BiVAD) support as a bridge to transplantation for selected patients with refractory heart failure due to biventricular dysfunction despite optimal pharmacologic and device treatment and who are otherwise eligible for heart transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early referral of the deteriorating patient and insertion of the LVAD before the onset of severe end-organ dysfunction is extremely important. Factors affecting early survival and reversal of organ dysfunction include chronicity of disease, development of right heart failure (which tends to occur with chronicity of disease), intrinsic end-organ functional reserve, co-morbid conditions, and age. Early intervention improves outcome enormously since the stress of surgery in a fragile patient with advanced disease contributes to poor short- and long-term outcomes.",
"   </p>",
"   <p>",
"    Our approach is similar to that recommended in the 2010 Heart Failure Society of America guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/13\">",
"     13",
"    </a>",
"    ] and is based upon the clinical evidence discussed below. (See",
"    <a class=\"local\" href=\"#H22787918\">",
"     'Clinical evidence'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Implantation of a continuous flow (second or third generation) device is generally preferred to use of a pulsatile flow (ie, first generation) device. Superior survival rates and lower rates of adverse events with the continuous flow device have been demonstrated in patients receiving the device as destination therapy. (See",
"    <a class=\"local\" href=\"#H601173\">",
"     'As destination therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22787927\">",
"     'As a bridge to transplantation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The United States Center for Medical Services has strict guidelines for placement of mechanical support as destination therapy in subjects who are not candidates for heart transplantation. Only an FDA approved device can be used and it must be placed in a device-approved facility. The patient must have a life expectancy less than two years and chronic Class IV CHF and have failed to respond to optimal medical therapy including beta blockers and ACE inhibitors (if tolerated) for at least 45 of the last 60 days or require intraaortic balloon support for seven days or intravenous inotropes for 14 days. Left ventricular ejection fraction should be &lt;25 percent and if the patient is ambulatory (not on intravenous inotropes), must have a peak VO2 &lt;14",
"    <span class=\"nowrap\">",
"     mL/kg/min.",
"    </span>",
"   </p>",
"   <p>",
"    The 2009 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association guidelines suggest consideration of an LVAD as destination therapy in highly selected patients with refractory end-stage HF and an estimated one-year mortality over 50 percent with medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=see_link&amp;anchor=H10#H10\">",
"     \"Prognosis of heart failure\", section on 'Survival in HF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2012 European Society of Cardiology guidelines include similar recommendations for bridge to transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/2\">",
"     2",
"    </a>",
"    ]. They recommend consideration of destination therapy in highly selected patients who have end-stage HF despite optimal pharmacological and device therapy and who are not suitable for heart transplantation but are expected to survive greater than one year with good functional status with LVAD therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164479177\">",
"    <span class=\"h2\">",
"     Considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considerations for placement of left ventricular mechanical support include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Assessment of the severity of heart failure",
"     </li>",
"     <li>",
"      Absence of a significant co-morbidity that would limit long term survival or quality of life.",
"     </li>",
"     <li>",
"      Need for biventricular support (ie, risk for right heart failure)",
"     </li>",
"     <li>",
"      Ability to tolerate long-term anticoagulation",
"     </li>",
"     <li>",
"      Adequate psychosocial support",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One major caveat in the selection of device patients is the need to evaluate the short- and long-term risk of right heart failure which impacts both morbidity and mortality with device therapy.&nbsp;The incidence of right heart failure in the perioperative period following left ventricular support in the past has varied from 5 to 50 percent, depending on the definition used.&nbsp;Some studies define right heart failure as the need for right ventricular (RV) mechanical support, whereas other studies define it as RV support, ECMO, or prolonged therapy with nitric oxide or intravenous inotropic therapy.&nbsp;In later trials with continuous flow pumps, the incidence of right heart failure has been approximately 6 percent. Predictors of RV failure in the perioperative period include hemodynamic and echocardiographic parameters such as RV stroke work index &lt;250, right atrial pressure &gt; 15 mmHg, severe RV dysfunction on echocardiography (including tricuspid annular plane systolic excursion [TAPSE] &lt;0.75 cm), renal insufficiency, hepatic dysfunction, and elevated pulmonary vascular resistance. Predictive models have been developed to estimate risk, but there is no consensus on how best to predict early right heart failure and no direct data on the development of chronic right heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22787918\">",
"    <span class=\"h1\">",
"     CLINICAL EVIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several clinical trials that form the basis for the use of ventricular assist device use as a bridge to transplantation or destination therapy. They are summarized in&nbsp;a table.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H601173\">",
"    <span class=\"h2\">",
"     As destination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The REMATCH (The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart failure) trial was the landmark study that validated the benefit of mechanical support for patients with end stage heart failure (",
"    <a class=\"graphic graphic_figure graphicRef85808 \" href=\"mobipreview.htm?13/49/14110\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/17\">",
"     17",
"    </a>",
"    ]. In the REMATCH",
"    <sup>",
"    </sup>",
"    trial, 129 patients with end-stage failure deemed ineligible for cardiac transplantation were randomly assigned to receive either optimal medical therapy or a HeartMate I (HMI) LVAD as permanent therapy. The median age was 69 years. One-year survival in the LVAD group was 52 percent compared to 25 percent in the optimal medical therapy group and two-year survival was 23 percent compared to 8 percent in the medical therapy group. Overall, all-cause mortality was reduced by 48 percent by insertion of the LVAD. NYHA class and measures of quality of life were significantly improved at one-year follow-up in the LVAD group.",
"   </p>",
"   <p>",
"    There was significant improvement in survival for LVAD patients enrolled during the second half of the trial (January 2000 to July 2001) compared with the first half (May 1998 to Dec 1999) reflecting improvements in patient management and device modifications. The one-year survival in the second half of the trial was 59 versus 44 percent in the first half and the two-year survival 38 versus 21 percent. A further study of patients implanted with the first generation Heartmate I device at four high volume centers following REMATCH from January 2003 to December 2004 showed improved 30-day and one-year survival, at 90 and 61 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the poor durability and high rates of infection of the first generation pulsatile devices (eg, HMI and XVE devices) were problematic. The continuous flow second generation devices (eg, HMII) have outperformed and have replaced first generation devices as supported by the results of a randomized trial comparing the HMII (n = 134) and HMI (n = 66) devices in patients receiving these devices between March 2005 and May 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/19\">",
"     19",
"    </a>",
"    ]. One- and two-year survival rates were significantly higher (68 and 58 percent) with the HMII compared to the HMI device (55 and 24 percent). The durability of HMII was significantly greater and the median duration of support was 1.7 years for the continuous flow device and 0.6 years for the pulsatile pump, with 86 and 76 percent, respectively, being discharged home on the device. There were significant reductions in the rates of major adverse events among patients with a continuous flow device including device-related infection (0.9 versus 0.48",
"    <span class=\"nowrap\">",
"     events/patient",
"    </span>",
"    year), non-device related infection (1.33 versus 0.76",
"    <span class=\"nowrap\">",
"     events/patient",
"    </span>",
"    year for local infection and 1.11 versus 0.39 for sepsis), right heart failure, respiratory failure, renal failure (0.34 versus 0.1",
"    <span class=\"nowrap\">",
"     events/patient",
"    </span>",
"    year), and cardiac arrhythmia. There was a 38 percent relative reduction in the rate of rehospitalization in patients with a continuous compared to a pulsatile device.",
"   </p>",
"   <p>",
"    Another study compared 281 patients who underwent HeartMate II (HMII) implantation for destination therapy from May 2007 to March 2009 (Mid Trial [MT]) to the initial 133 HMII patients who underwent implantation from March 2005 to May 207 (Early Trial [ET]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/20\">",
"     20",
"    </a>",
"    ]. Compared to the ET group, patients in the MT group had significant reduced adverse event rates for bleeding requiring transfusions (1.66 versus 1.13",
"    <span class=\"nowrap\">",
"     events/patient-year),",
"    </span>",
"    sepsis (0.38 versus 0.27), device-related infections (0.47 versus 0.27), and hemorrhagic stroke (0.07 versus 0.03",
"    <span class=\"nowrap\">",
"     events/patient-year).",
"    </span>",
"    Hemorrhagic stroke was the most common cause of death in the Early Trial group (8 percent), which was significantly reduced to 2 percent in the Mid Trial group. Survival at one year in the MT group was 73 versus 68 percent in the ET group. Quality improvements were significant in both the groups, with a trend to better quality of life in the MT group (p = 0.08). Kaplan Meier survival at 12 and 24 months for the MT group was 73 and 63 percent compared to the ET experience of 68 and 58 percent.",
"   </p>",
"   <p>",
"    The ENDURANCE trial has completed enrollment of 450 non-transplant eligible severe heart failure patients randomized 2:1 to HeartWare and HMII.&nbsp;Results are pending.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22787927\">",
"    <span class=\"h2\">",
"     As a bridge to transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rates of survival to transplantation in observational studies have ranged from 60 to 75 percent with first generation pulsatile pumps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/21-23\">",
"     21-23",
"    </a>",
"    ], with the largest trial being the multicenter evaluation of the Heartmate I (HMI) in which 71 percent of 280 patients survived to transplantation or device removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/22\">",
"     22",
"    </a>",
"    ]. Observed outcomes for second and third generation pumps are better than for first generation devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/24,25\">",
"     24,25",
"    </a>",
"    ] with survival to transplant greater than 90 percent &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective multicenter study enrolled a primary cohort of 133 NYHA Class IV patients from March 2005 to May 2006 who underwent implantation of a Heartmate II (HMII) device as a bridge to transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/24\">",
"     24",
"    </a>",
"    ]. All were on inotropic support (except 11 percent who were intolerant because of arrhythmias) and 41 percent were also intraaortic balloon pump dependant. After 180 days, 100 patients (75 percent) had reached the principal outcome of transplantation, recovery, or survival on ongoing support with eligibility for transplantation. An additional five patients (4 percent) were alive but not yet eligible for transplantation and another three (2 percent) were alive but had had a device replacement. Overall survival was 81 percent at six months. Of note, four patients removed themselves from the transplant waiting list as they preferred to continue mechanical support. The overall survival of patients who underwent transplantation recovered their cardiac function or continued to receive mechanical circulatory support while remaining a candidate for transplantation was estimated to be 70 percent at one year. Patients on HMII support had improvements in NYHA class, six-minute walk, functional status, and quality of life.",
"   </p>",
"   <p>",
"    Enrollment continued following the primary cohort and a later study reported outcomes for 281 of 469 patients enrolled by April 2008 who had completed study end points or had at least 18 months of follow-up with ongoing device support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/26\">",
"     26",
"    </a>",
"    ]. Of these, 79 percent had either received a transplant, been explanted due to myocardial recovery, or remained alive on a VAD at 18 months. Actuarial survival on support was 82, 73, and 72 percent at six months, one year, and 18 months. The freedom from major device malfunction resulting in death or device replacement for all causes was 96, 93, and 92 percent at six months, one year, and 18 months. Of the 56 percent that received a transplant, post-transplant survival was 96 percent at 30 days and 86 percent at one year.",
"   </p>",
"   <p>",
"    A post-approval",
"    <sup>",
"    </sup>",
"    study was performed as required by the FDA",
"    <sup>",
"    </sup>",
"    to determine whether the results with the HM II device in a commercial",
"    <sup>",
"    </sup>",
"    setting were comparable to other available devices for the same",
"    <sup>",
"    </sup>",
"    indication. The study evaluated the first 169 consecutive",
"    <sup>",
"    </sup>",
"    HM II patients enrolled in the national INTERMACS registry from April through August 2008 at 52 US centers",
"    <sup>",
"    </sup>",
"    and followed for at least one year after implant who",
"    <sup>",
"    </sup>",
"    were listed for transplant or likely to be listed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/27\">",
"     27",
"    </a>",
"    ]. A comparison",
"    <sup>",
"    </sup>",
"    group (COMP) included all patients enrolled",
"    <sup>",
"    </sup>",
"    in the INTERMACS registry with other types of LVADs for the same BTT indication in the same time period (n = 169 at 27 centers). In the COMP group, 135 (80 percent) received the electric HeartMate",
"    <sup>",
"    </sup>",
"    XVE LVAD and 34 (20 percent) received the pneumatic Thoratec Implantable",
"    <sup>",
"    </sup>",
"    Ventricular Assist Device. Operative 30-day mortality",
"    <sup>",
"    </sup>",
"    for HM II was 4 versus 11 percent for the COMP group. The percentage of patients",
"    <sup>",
"    </sup>",
"    reaching transplant, cardiac recovery, or ongoing LVAD support",
"    <sup>",
"    </sup>",
"    by six months was 91 percent for HM II and 80 percent for the COMP group. Kaplan-Meier survival over 12 months was significantly higher for HM II versus COMP patients with estimated survival rates of 90 versus 79 percent at six months and 85 versus 70 at 12 months. Rates of infection, renal dysfunction, respiratory dysfunction, bleeding, cardiac arrhythmias, and hypertension were lower for HM",
"    <sup>",
"    </sup>",
"    II versus COMP. There was no difference in the",
"    <sup>",
"    </sup>",
"    incidence of stroke, but non-stroke neurologic",
"    <sup>",
"    </sup>",
"    dysfunction was less in the HM II group.",
"    <sup>",
"    </sup>",
"   </p>",
"   <p>",
"    Data are also starting to emerge for the third-generation devices. Fifty patients were enrolled between March 2006 and December 2008 at five centers in Europe and Australia to receive the Heartware device as a BTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/28\">",
"     28",
"    </a>",
"    ]. Survival to heart transplantation, myocardial recovery, and HVAD pump explant at 6, 12, and 24 months was 90, 84, and 79 percent, respectively (",
"    <a class=\"graphic graphic_figure graphicRef85804 \" href=\"mobipreview.htm?30/26/31150\">",
"     figure 7",
"    </a>",
"    ). This compares to SHFM estimated survival rates if medical therapy was continued of 73 percent at six months, 58 percent at one year, and 40 percent at two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/6\">",
"     6",
"    </a>",
"    ] . Symptom burden, quality of life, physical limitations, and overall functional status were significantly improved across all testing periods to six months. There were no mechanical failures. The readmission rate for medical complications was 1.2",
"    <span class=\"nowrap\">",
"     admissions/patient",
"    </span>",
"    year which is 74 percent less than the average admission rate of this group for the year before their HVAD implants. Patients who were bridged to a heart transplant had a six-month survival of 95 percent after transplant.",
"   </p>",
"   <p>",
"    A prospective multicenter observational US study compared outcomes in 140 patients receiving the HeartWare device with outcomes in 499 patients contemporaneously receiving commercially available (likely nearly all axial continuous flow) devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/25\">",
"     25",
"    </a>",
"    ]. Success defined as survival on the originally implanted device, transplantation, or explantation for ventricular recovery at 180 days was 90.7 percent for HeartWare patients and 90.1 percent for controls. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22787941\">",
"    <span class=\"h2\">",
"     As a bridge to recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of patients supported with an LVAD have shown significant improvement in their myocardial function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/22\">",
"     22",
"    </a>",
"    ] and there is now compelling evidence that prolonged near complete unloading of the left ventricle with the use of an LVAD is associated with structural reverse remodeling that can be accompanied by functional improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/6\">",
"     6",
"    </a>",
"    ], which can be sufficient in some cases to allow explantation of the device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/6,7,22,29\">",
"     6,7,22,29",
"    </a>",
"    ]. However, the exact proportion of patients in which this is possible is unknown and was initially reported to be only 5 to 24 percent in various series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using a strategy that combines pharmacologic therapy and mechanical cardiac support as described above (see",
"    <a class=\"local\" href=\"#H22787818\">",
"     'Bridge to recovery'",
"    </a>",
"    above), it was possible to promote recovery and allow removal of the pump in 73 percent of a prospective series of 15 patients with chronic heart failure due to dilated cardiomyopathy receiving the Heartmate I device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/6\">",
"     6",
"    </a>",
"    ]. These patients remain well with good quality life 12 years later, suggesting that recovery is durable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/33\">",
"     33",
"    </a>",
"    ]. Subsequently, the same protocol was applied to a prospective series of 20 patients with dilated cardiomyopathy receiving the Heartmate II continuous flow pump and 60 percent recovered sufficiently for the pump to be removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/7\">",
"     7",
"    </a>",
"    ]. Hence, LVADs can be used as a platform for myocardial recovery. In these patients, we have also observed reversal of many molecular changes seen at the time of LVAD implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/34-38\">",
"     34-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1787546\">",
"    <span class=\"h2\">",
"     Biventricular support",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who require long-term biventricular support, the limited device options include the Thoratec PVAD used as a biventricular device (BiVAD) (which has only intermediate durability), the total artificial heart (TAH), and investigational compassionate use of HeartWare as biventricular support. (See",
"    <a class=\"local\" href=\"#H22787839\">",
"     'Thoratec paracorporeal ventricular assist device (PVAD)'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H22787897\">",
"     'HeartWare'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1787553\">",
"     'Total artificial heart'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1787868\">",
"    <span class=\"h3\">",
"     Biventricular device",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving BiVAD support are more critically ill at the time of mechanical cardiac support implantation and have lower survival rates and higher serious adverse event rates than patients requiring LVAD support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/1\">",
"     1",
"    </a>",
"    ]. In an analysis of data on 1646 patients in the INTERMACS database, patients receiving BiVAD support presented with more critical clinical profiles and survival at six months was 56 percent for patients receiving BiVADs as compared to 86 percent for patients receiving LVADs. Significantly higher rates of bleeding, infection, neurologic events, and device failure were seen in the BiVAD group compared to the LVAD group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1787553\">",
"    <span class=\"h3\">",
"     Total artificial heart",
"    </span>",
"    &nbsp;&mdash;&nbsp;An observational multicenter prospective clinical study in 81 patients receiving a total artificial heart demonstrated a one-year survival rate of 70 percent and a 79 percent rate of survival to cardiac transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/12\">",
"     12",
"    </a>",
"    ]. Survival rates at one and five years post-cardiac transplantation were 86 and 64 percent, respectively.&nbsp;A report from the University of Arizona described the outcomes of 100 patients bridged with the total artificial heart from January 1993 to December 2009; survival to transplant was 68 percent. Survival post-transplantation was just 76.8 and 60.5 percent at one and five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1787753\">",
"    <span class=\"h3\">",
"     Comparison of type of biventricular support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data comparing biventricular support devices are available. A series of 383 patients receiving biventricular support included 255 receiving paracorporeal BiVADs (eg, Thoratec Paracorporeal VAD), 90 patients receiving a total artificial heart (CardioWest), and 38 patients receiving an implantable BiVAD (Thoratec Implantable VAD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37785/abstract/41\">",
"     41",
"    </a>",
"    ]. After a mean of 46&plusmn;83 days of support, 37 percent of patients died. Mortality was similar in the three patient groups. The frequency of stroke during mean 23 month follow-up was lower in TAH patients than in patients with either paracorporeal or implantable BiVADs (16 versus 57 and 61 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14204661\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend implantation of a left ventricular assist device (LVAD) as a bridge to transplantation for selected patients with refractory heart failure due to left ventricular dysfunction despite optimal pharmacologic and device treatment who are otherwise eligible for heart transplantation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H164479067\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22787927\">",
"       'As a bridge to transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest implantation of biventricular mechanical support (eg, BiVAD) as a bridge to transplantation for selected patients with refractory heart failure due to biventricular dysfunction despite optimal pharmacologic and device treatment and device treatment and who are otherwise eligible for heart transplantation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H164479067\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1787546\">",
"       'Biventricular support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend implantation of an LVAD as destination therapy in selected patients with refractory heart failure despite optimal pharmacologic and device treatment and expert heart failure care who are not candidates for heart transplantation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H164479067\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H601173\">",
"       'As destination therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest an LVAD as a bridge to decision (on heart transplantation or VAD destination therapy) in selected patients with refractory heart failure and hemodynamic instability",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      compromised end-organ function, with relative contraindications to heart transplantation that are expected to improve with time or improved hemodynamics (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H164479067\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H599696\">",
"       'Bridge to decision'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In this clinical setting, support from a device may allow renal function, nutritional status, and pulmonary vascular resistance to improve over several weeks or months prior to subsequent transplantation. Transplantation should be considered in such patients only after these improvements have occurred.",
"     </li>",
"     <li>",
"      Implantation of a continuous flow device is preferred to use of a pulsatile flow device. Superior survival rates and lower rates of adverse events with the continuous flow device have been demonstrated most directly in patients receiving destination therapy. (See",
"      <a class=\"local\" href=\"#H164479067\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H601173\">",
"       'As destination therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H364713663\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Drs. Valluvan Jeevanandam and Howard Eisen for their contributions as authors to previous versions of this topic review, as well as Wilson Colucci for his contributions as Section Editor.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/1\">",
"      Cleveland JC Jr, Naftel DC, Reece TB, et al. Survival after biventricular assist device implantation: an analysis of the Interagency Registry for Mechanically Assisted Circulatory Support database. J Heart Lung Transplant 2011; 30:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/2\">",
"      McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/3\">",
"      Aurora P, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: thirteenth official pediatric lung and heart-lung transplantation report--2010. J Heart Lung Transplant 2010; 29:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/4\">",
"      Lietz K, Miller LW. Improved survival of patients with end-stage heart failure listed for heart transplantation: analysis of organ procurement and transplantation network/U.S. United Network of Organ Sharing data, 1990 to 2005. J Am Coll Cardiol 2007; 50:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/5\">",
"      Kirklin JK, Naftel DC, Kormos RL, et al. The Fourth INTERMACS Annual Report: 4,000 implants and counting. J Heart Lung Transplant 2012; 31:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/6\">",
"      Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006; 355:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/7\">",
"      Birks EJ, George RS, Hedger M, et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation 2011; 123:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/8\">",
"      Yacoub MH. A novel strategy to maximize the efficacy of left ventricular assist devices as a bridge to recovery. Eur Heart J 2001; 22:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/9\">",
"      Wong K, Boheler KR, Bishop J, et al. Clenbuterol induces cardiac hypertrophy with normal functional, morphological and molecular features. Cardiovasc Res 1998; 37:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/10\">",
"      Wong K, Boheler KR, Petrou M, Yacoub MH. Pharmacological modulation of pressure-overload cardiac hypertrophy: changes in ventricular function, extracellular matrix, and gene expression. Circulation 1997; 96:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/11\">",
"      Haj-Yahia S, Birks EJ, Rogers P, et al. Midterm experience with the Jarvik 2000 axial flow left ventricular assist device. J Thorac Cardiovasc Surg 2007; 134:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/12\">",
"      Meyer A, Slaughter M. The total artificial heart. Panminerva Med 2011; 53:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/13\">",
"      Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/14\">",
"      Drakos SG, Janicki L, Horne BD, et al. Risk factors predictive of right ventricular failure after left ventricular assist device implantation. Am J Cardiol 2010; 105:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/15\">",
"      Matthews JC, Koelling TM, Pagani FD, Aaronson KD. The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol 2008; 51:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/16\">",
"      Fitzpatrick JR 3rd, Frederick JR, Hsu VM, et al. Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. J Heart Lung Transplant 2008; 27:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/17\">",
"      Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/18\">",
"      Long JW, Kfoury AG, Slaughter MS, et al. Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study. Congest Heart Fail 2005; 11:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/19\">",
"      Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/20\">",
"      Park SJ, Milano CA, Tatooles AJ, et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail 2012; 5:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/21\">",
"      Navia JL, McCarthy PM, Hoercher KJ, et al. Do left ventricular assist device (LVAD) bridge-to-transplantation outcomes predict the results of permanent LVAD implantation? Ann Thorac Surg 2002; 74:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/22\">",
"      Frazier OH, Rose EA, Oz MC, et al. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 2001; 122:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/23\">",
"      Sun BC, Catanese KA, Spanier TB, et al. 100 long-term implantable left ventricular assist devices: the Columbia Presbyterian interim experience. Ann Thorac Surg 1999; 68:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/24\">",
"      Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007; 357:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/25\">",
"      Aaronson KD, Slaughter MS, Miller LW, et al. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation 2012; 125:3191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/26\">",
"      Pagani FD, Miller LW, Russell SD, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 2009; 54:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/27\">",
"      Starling RC, Naka Y, Boyle AJ, et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 2011; 57:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/28\">",
"      Strueber M, O'Driscoll G, Jansz P, et al. Multicenter evaluation of an intrapericardial left ventricular assist system. J Am Coll Cardiol 2011; 57:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/29\">",
"      Simon MA, Kormos RL, Murali S, et al. Myocardial recovery using ventricular assist devices: prevalence, clinical characteristics, and outcomes. Circulation 2005; 112:I32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/30\">",
"      Mancini DM, Beniaminovitz A, Levin H, et al. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation 1998; 98:2383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/31\">",
"      Dandel M, Weng Y, Siniawski H, et al. Prediction of cardiac stability after weaning from left ventricular assist devices in patients with idiopathic dilated cardiomyopathy. Circulation 2008; 118:S94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/32\">",
"      Farrar DJ, Holman WR, McBride LR, et al. Long-term follow-up of Thoratec ventricular assist device bridge-to-recovery patients successfully removed from support after recovery of ventricular function. J Heart Lung Transplant 2002; 21:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/33\">",
"      George RS, Yacoub MH, Bowles CT, et al. Quality of life after removal of left ventricular assist device for myocardial recovery. J Heart Lung Transplant 2008; 27:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/34\">",
"      Birks EJ, Hall JL, Barton PJ, et al. Gene profiling changes in cytoskeletal proteins during clinical recovery after left ventricular-assist device support. Circulation 2005; 112:I57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/35\">",
"      Hall JL, Birks EJ, Grindle S, et al. Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy. Eur Heart J 2007; 28:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/36\">",
"      Latif N, Yacoub MH, George R, et al. Changes in sarcomeric and non-sarcomeric cytoskeletal proteins and focal adhesion molecules during clinical myocardial recovery after left ventricular assist device support. J Heart Lung Transplant 2007; 26:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/37\">",
"      Cullen ME, Yuen AH, Felkin LE, et al. Myocardial expression of the arginine:glycine amidinotransferase gene is elevated in heart failure and normalized after recovery: potential implications for local creatine synthesis. Circulation 2006; 114:I16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/38\">",
"      Terracciano CM, Harding SE, Adamson D, et al. Changes in sarcolemmal Ca entry and sarcoplasmic reticulum Ca content in ventricular myocytes from patients with end-stage heart failure following myocardial recovery after combined pharmacological and ventricular assist device therapy. Eur Heart J 2003; 24:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/39\">",
"      Copeland JG, Smith RG, Arabia FA, et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med 2004; 351:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/40\">",
"      Copeland JG, Copeland H, Gustafson M, et al. Experience with more than 100 total artificial heart implants. J Thorac Cardiovasc Surg 2012; 143:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37785/abstract/41\">",
"      Kirsch M, Mazzucotelli JP, Roussel JC, et al. Survival after biventricular mechanical circulatory support: does the type of device matter? J Heart Lung Transplant 2012; 31:501.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3459 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-382E3F64B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_57_37785=[""].join("\n");
var outline_f36_57_37785=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14204661\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23100009\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22787795\">",
"      CATEGORIES OF USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22787804\">",
"      Bridge to transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H599696\">",
"      Bridge to decision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22787811\">",
"      Destination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22787818\">",
"      Bridge to recovery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H601056\">",
"      DEVICE OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H601048\">",
"      FIRST GENERATION DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22787832\">",
"      HeartMate I device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22787839\">",
"      Thoratec paracorporeal ventricular assist device (PVAD)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22787846\">",
"      Novacor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22787853\">",
"      SECOND GENERATION DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22787860\">",
"      HeartMate II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22787867\">",
"      Jarvik 2000",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22787874\">",
"      Berlin Heart INCOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22787881\">",
"      MicroMed DeBakey",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22787888\">",
"      THIRD GENERATION PUMPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22787897\">",
"      HeartWare",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22787904\">",
"      DuraHeart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1787388\">",
"      BIVENTRICULAR SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1787395\">",
"      Total artificial heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14205254\">",
"      CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H164479067\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H164479177\">",
"      Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22787918\">",
"      CLINICAL EVIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H601173\">",
"      As destination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22787927\">",
"      As a bridge to transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22787941\">",
"      As a bridge to recovery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1787546\">",
"      Biventricular support",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1787868\">",
"      - Biventricular device",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1787553\">",
"      - Total artificial heart",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1787753\">",
"      - Comparison of type of biventricular support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14204661\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H364713663\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3459\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3459|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/11/42165\" title=\"figure 1\">",
"      HeartMate XVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/7/9333\" title=\"figure 2\">",
"      HeartMate II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/37/23125\" title=\"figure 3\">",
"      Jarvik 2000 LVAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/52/1859\" title=\"figure 4\">",
"      HeartWare LVAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/3/4146\" title=\"figure 5\">",
"      The SynCardia Total Artificial Heart",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/49/14110\" title=\"figure 6\">",
"      Survival with HMII versus medical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/26/31150\" title=\"figure 7\">",
"      Actuarial success rates with HVAD and predicted survival rates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3459|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/29/477\" title=\"table 2\">",
"      Risk factors for death in adult destination therapy patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15911?source=related_link\">",
"      Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18617?source=related_link\">",
"      Genetic and cellular therapy in heart failure and myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34297?source=related_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=related_link\">",
"      Prognosis of heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_57_37786="Etiology, clinical manifestations, and diagnosis of vascular dementia";
var content_f36_57_37786=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology, clinical manifestations, and diagnosis of vascular dementia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/57/37786/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/57/37786/contributors\">",
"     Clinton B Wright, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/57/37786/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/57/37786/contributors\">",
"     Steven T DeKosky, MD, FAAN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/57/37786/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/57/37786/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/57/37786/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/57/37786/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular dementia (VaD) has a long history. VaD was first described in the late 19th century by Binswanger and Alzheimer who also recognized and described a variety of underlying pathologic mechanisms including the role of multiple infarctions and chronic ischemia. For nearly 50 years this was held to be the predominant form of dementia. Subsequently, pathologic studies demonstrated that the amyloid plaques and neurofibrillary tangles of Alzheimer disease (AD) were much more common in the brains of the demented elderly than previously thought [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/1\">",
"     1",
"    </a>",
"    ]; chronic ischemic injury was thought to be quite rare, and VaD was understood as the sequelae of recurrent strokes or \"multi-infarct dementia\" (MID) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/2\">",
"     2",
"    </a>",
"    ]. With the advent of sophisticated neuroimaging techniques, computed tomography (CT) and magnetic resonance imaging (MRI), in the latter part of the twentieth century, the high prevalence of chronic vascular injury in the brain was appreciated, and interest in the role of vascular disease, including the role of progressive ischemic injury, on cognitive decline reemerged.",
"   </p>",
"   <p>",
"    Despite this surge of interest, certain issues impede progress. There are no pathologic criteria for the diagnosis of VaD, as there are for AD. A number of clinical diagnostic criteria exist but are poorly validated and inconsistently applied.",
"   </p>",
"   <p>",
"    Even basic terminology requires clarification. As an example, the traditional definition of dementia was originally developed in the context of AD in which memory loss occurs prominently and early on in the disease. However, in patients with cognitive deficits ultimately attributable to VaD, memory impairment appears somewhat later, and these patients may have significant cognitive disability long before they meet criteria for dementia.",
"   </p>",
"   <p>",
"    This has led to the proposed concept of \"vascular cognitive impairment\" or VCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards, recognizing the limitations of current diagnostic criteria for both AD and VaD, promulgate the use of VCI as \"cognitive impairment that is caused by or associated with vascular factors\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/5\">",
"     5",
"    </a>",
"    ]. Cognitive deficits associated with vascular disease that don't meet criteria for dementia is labelled \"vascular cognitive impairment, no dementia\" (vCIND). This is somewhat analogous to the more accepted term \"mild cognitive impairment\" or MCI, also known as \"cognitive impairment, no dementia\" or CIND [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/6\">",
"     6",
"    </a>",
"    ]. Criteria as to what deficits qualify as cognitive impairment are somewhat loose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/6\">",
"     6",
"    </a>",
"    ]. Use of the term Binswanger's disease to apply to VaD characterized by severe white matter disease associated with longstanding hypertension is no longer accepted; the volume of the white matter damage sufficient to cause VaD is not known and there are no accepted diagnostic criteria for this entity.",
"   </p>",
"   <p>",
"    At the foundation of some of these problems is the fact that cerebrovascular disease is itself a heterogeneous disorder, with a variety of pathophysiologic mechanisms and clinical manifestations. At present, the entity of VaD is best understood as a heterogeneous syndrome rather than a distinct disorder, in which the underlying cause is cerebrovascular disease in some form and its ultimate manifestation is dementia.",
"   </p>",
"   <p>",
"    This topic will review the etiology, pathogenesis, clinical manifestations, and diagnosis of vascular dementia. The prevention, treatment, and prognosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10104?source=see_link\">",
"     \"Treatment and prevention of vascular dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using traditional definitions, vascular dementia (VaD) is the second most common form of dementia after Alzheimer disease (AD) in most clinical series, and it makes up 10 to 20 percent of cases in North America and Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In one pathological, population-based study, cerebral microinfarcts accounted for an estimated 33 percent of the population attributable risk for dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/9\">",
"     9",
"    </a>",
"    ]. The relative preponderance of the two disorders may be reversed in other countries, such as Japan and China [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differences in screening methods and diagnostic criteria lead to variability in reported prevalence and incidence, but some trends seem consistent. Estimated prevalences of VaD vary from 1.2 to 4.2 percent of individuals over 65 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/12\">",
"     12",
"    </a>",
"    ]. In the European collaborative study of population-based cohorts, the pooled estimate of VaD prevalence was 1.6 percent in those over the age of 65 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/7\">",
"     7",
"    </a>",
"    ]. The prevalence increased successively with increasing age deciles to about 3.6 percent in men and 5.8 percent in women, over the age of 90 years. In Canada, similar age trends were seen for VaD as well as the entire group of vascular cognitive impairment (VCI); the latter increased from 2.0 percent in those 65 to 74 years to 13.7 percent in those over 85 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Age-adjusted incident rates (IRs) are overall estimated at 6 to 12 cases per 1000 person years over the age of 70 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/12\">",
"     12",
"    </a>",
"    ]. In Canada, the incidence increased from 0.9 per 1000 person years in those aged 65 to 69 years to 6.74 in those greater than 90 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/14\">",
"     14",
"    </a>",
"    ]. Similar trends were seen in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/8\">",
"     8",
"    </a>",
"    ] and the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/15\">",
"     15",
"    </a>",
"    ]. A meta-analysis of 23 studies from around the world, despite much variability between studies, showed an overall trend for an exponential increase of incident VaD with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some prevalence and incidence data suggest an overall higher preponderance of the disease in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/8\">",
"     8",
"    </a>",
"    ], while others note this only in the younger age groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/7,16\">",
"     7,16",
"    </a>",
"    ], and still others note no gender differences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/13-15,17,18\">",
"     13-15,17,18",
"    </a>",
"    ]. One study found no significant difference in IRs in blacks versus whites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/15\">",
"     15",
"    </a>",
"    ]; another found a higher incidence in blacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;While it is expected that VaD would share risk factors with cerebrovascular disease, the evidence is not compelling. Variable degrees of association and, in some studies, no associations have been found for hypertension, diabetes and insulin resistance, dyslipidemia, and heart disease with VaD in population-based cohorts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/14,17,19-26\">",
"     14,17,19-26",
"    </a>",
"    ]. These differences might be partly explained by differences in control groups; some studies specifically excluded patients with cerebrovascular disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other forms of dementia, while others did not.",
"   </p>",
"   <p>",
"    The metabolic syndrome, a cluster of cardiovascular risk factors that include obesity, hypertension, insulin resistance, and dyslipidemia, was weakly associated with incident vascular dementia in the large Honolulu Aging study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/27\">",
"     27",
"    </a>",
"    ]. Another similarly-sized population-based cohort study found a stronger association (HR = 3.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/28\">",
"     28",
"    </a>",
"    ]. When neuropsychiatric testing was performed in a smaller cohort of patients with the metabolic syndrome, deficits in executive dysfunction were noted, suggesting that the metabolic syndrome may be a prodromal state of vascular cognitive impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Poststroke dementia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5885880\">",
"    <span class=\"h3\">",
"     Clinical stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have demonstrated a high incidence of cognitive impairment and dementia after stroke with rates ranging from 6 to 32 percent in patients followed from three months to 20 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/30-43\">",
"     30-43",
"    </a>",
"    ]. In one study that examined patients with lacunar stroke (presumably related to small vessel occlusive disease), mild cognitive impairment or dementia was present in nearly half [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/44\">",
"     44",
"    </a>",
"    ]. Short-term assessments (&lt;1 year) are likely to significantly over-diagnose post-stroke dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/45\">",
"     45",
"    </a>",
"    ]. In one study that used a control group, stroke was associated with a 3.83 relative risk (RR) for dementia compared with nonstroke hospitalized controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Population-based studies have reported somewhat conflicting results regarding the risk of dementia after stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. A pooled analysis that included both population-based and hospital-based cohorts found that 10 percent of patients with a first stroke had pre-stroke dementia and 10 percent subsequently developed dementia, while more than one-third of patients developed dementia after a recurrent stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/50\">",
"     50",
"    </a>",
"    ]. Mild cognitive impairment before stroke increases the likelihood of post-stroke dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/49,51\">",
"     49,51",
"    </a>",
"    ]. In another meta-analysis, a stroke history was observed to confer a two-fold higher risk of dementia in patients younger than, but not older than 85 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Age is nearly uniformly found to increase the risk of dementia after stroke. Other risk factors commonly, but not uniformly, identified in this setting include increased severity of the index stroke, atrial fibrillation, the presence of white matter disease and cortical atrophy (particularly in the temporal lobe) on imaging, multiple clinical events or lesions on neuroimaging, hypertension, obesity, elevated homocysteine or high density lipoprotein levels, and diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/32-38,41,53-60\">",
"     32-38,41,53-60",
"    </a>",
"    ]. Some studies indicate that stroke in the left hemisphere, particularly those with associated aphasia, is a risk factor. Evidence of premorbid cognitive impairment is also a risk factor, while higher educational level favorably modifies the risk for post-stroke cognitive decline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/38,49,61,62\">",
"     38,49,61,62",
"    </a>",
"    ]. In fact, one study found that mild cognitive impairment was a prerequisite for incident dementia after stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/49\">",
"     49",
"    </a>",
"    ]. Another long-term population based study found that baseline memory impairment and rates of memory decline were greater in patients who later developed a stroke compared to those who remained stroke free [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/63\">",
"     63",
"    </a>",
"    ]. Most studies have not identified gender as a risk factor, but two identified a higher incidence in females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/31,35\">",
"     31,35",
"    </a>",
"    ] and one in males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While some studies indicate that most cases accrue early after stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/17,64\">",
"     17,64",
"    </a>",
"    ], others have demonstrated fairly steady accrual of cases over years of annual screening evaluations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/30,32,37\">",
"     30,32,37",
"    </a>",
"    ]. This is complicated by the fact that cognitive status after stroke is unstable; comparisons between three-month and one-year assessments reveal that while some patients worsen, others improve, and in some cases the incidence of dementia is actually less at one year than it is at three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/45,57,65,66\">",
"     45,57,65,66",
"    </a>",
"    ]. In one cohort study, recurrent stroke was associated with greater cognitive decline compared with patients with a single stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/38\">",
"     38",
"    </a>",
"    ]. Most studies did not identify cases as AD or VaD; in those that did, VaD rather than AD was the diagnosis in most cases (51 to 66.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/30,32,64\">",
"     30,32,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from the National Long-Term Care Survey suggest that post-stroke dementia is an increasing problem, with age-standardized rates increasing from 0.043 between 1984 to 1990 to 0.080 between 1991 to 2001 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/67\">",
"     67",
"    </a>",
"    ]. A concomitant decline in stroke case-fatality rates was also reported, which may contribute to the increased rate of dementia. Cognitive impairment after stroke is also an important contributor to nursing home placement and shortens survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/68-70\">",
"     68-70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Subclinical \"silent\" brain infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically silent brain infarction is also a risk factor for subsequent cognitive decline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/41,71,72\">",
"     41,71,72",
"    </a>",
"    ]. In one study, nondemented patients without a stroke history but with evidence of cerebral infarction on magnetic resonance imaging (MRI) had double the risk of dementia over five years of follow-up compared with controls with normal MRIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/73\">",
"     73",
"    </a>",
"    ]. The presence of multiple silent infarctions was more strongly associated with subsequent cognitive decline than single lesions, and the decline in cognitive function was restricted to those with accrual of silent infarcts on follow-up imaging. The presence of white matter changes and subcortical atrophy also was associated with risk of dementia. A clinicopathologic study of 72 individuals without Alzheimer pathology found a significant correlation between clinically silent thalamic and basal ganglia lacunes and clinical dementia rating scores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least three common pathological entities are thought to contribute substantively to vascular dementia (VaD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/75\">",
"     75",
"    </a>",
"    ]):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large artery infarctions, usually cortical, sometimes also or exclusively subcortical in location.",
"     </li>",
"     <li>",
"      Small artery infarctions or lacunes, exclusively subcortical, in the distribution of small penetrating arteries, affecting the basal ganglia, caudate, thalamus, and internal capsule as well as the cerebellum and brainstem [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/72,76\">",
"       72,76",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/59/4026?source=see_link\">",
"       \"Lacunar infarcts\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic subcortical ischemia occurring in the distribution of small arteries in the periventricular white matter and leading to selective loss of tissue elements in order of their selective vulnerability - neuron, oligodendrocyte, myelinated axon, astrocyte, and endothelial cell [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The small artery disease underlying both lacunar infarctions and subcortical ischemia is most commonly attributed to lipohyalinosis or microatheroma affecting the small penetrating arteries. These are particularly prevalent in the elderly and those with hypertension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diabetes. Sharing a primary vascular pathology, it is not surprising that lacunar infarctions and chronic ischemic changes in the white matter more often occur together than apart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/78\">",
"     78",
"    </a>",
"    ]. Other studies have found that the presence of cerebral microbleeds in the deep hemispheric and infratentorial regions and retinopathy (both of which are other clinical manifestations attributed to small artery disease) are associated with vascular cognitive impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. Gadolinium-enhanced MRI studies have found evidence of diffuse blood-brain barrier dysfunction throughout the white matter among patients with lacunar infarction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    white matter lesions, a finding not seen in patients with cortical stroke or stroke-free controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. It is not clear if this finding is pathogenically linked to the diffuse chronic subcortical ischemia. Some subcategorize this entity as subcortical VaD, and the term Binswanger's disease generally refers to this subset of VaD patients.",
"   </p>",
"   <p>",
"    Each of the above findings is common. They are not mutually exclusive and in fact, share underlying risk factors. Any one or more may be present in a patient with VaD and contribute independently to cognitive disabilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/84\">",
"     84",
"    </a>",
"    ]. These also may be found in patients with Alzheimer disease (AD) and in nondemented individuals.",
"   </p>",
"   <p>",
"    While intracerebral hemorrhage is potentially a contributor to VaD, it is not generally described, perhaps because these are less likely to be recurrent events. Subarachnoid hemorrhage, cognitive impairment after cardiac bypass surgery, hypoxic ischemic encephalopathy, and watershed infarction in the setting of profound hypotension are vascular events that may cause permanent, devastating cognitive impairment. However, these are more appropriately considered under the rubric of a \"static encephalopathy\" rather than dementia because of the lack of expected progression.",
"   </p>",
"   <p>",
"    While the volume of damaged tissue appears to be important in producing VaD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/85-87\">",
"     85-87",
"    </a>",
"    ], at least one study suggested that the absolute number of infarcts, not the individual or aggregate infarct volume, was important in producing VaD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/88\">",
"     88",
"    </a>",
"    ]. More critical, however, is the anatomic distribution of ischemic injury. Certain sites in the brain are \"strategic\" for producing deficits that cause, simulate, or add to a dementia syndrome. These may be cortical (hippocampus, angular gyrus, gyrus cinguli, frontal lobe) or subcortical (thalamus, fornix, basal forebrain, caudate, globus pallidus, and the genu or anterior limb of the internal capsule) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/89-93\">",
"     89-93",
"    </a>",
"    ]. Damage to the thalamus, in particular, appears to be an important determinant of cognitive impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. Because of the prominent and disabling cognitive effects of even a single stroke in these areas, these patients are often labeled as having \"strategic infarct dementia,\" although in such cases the course may be static rather than progressive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential causes of cerebral infarcts, both large and small, are numerous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=see_link\">",
"     \"Overview of the evaluation of stroke\"",
"    </a>",
"    .) Two entities, cerebral amyloid angiopathy and CADASIL, require specific discussion in this context.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RELATED CONDITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cerebral amyloid angiopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral amyloid angiopathy (CAA) is a disorder caused by accumulation of amyloid in cerebral vessels, and it leads to multiple lobar hemorrhages, microbleeds, or infarctions. CAA is prevalent in those with AD, and dementia in these individuals has been traditionally ascribed to AD. However, extensive CAA can also cause ischemic white matter damage, a complication that is presumably related to diffuse narrowing of penetrating cortical vessels by amyloid deposits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/96,97\">",
"     96,97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These patients can present with VaD. Population-based autopsy series suggest that CAA is associated with cognitive impairment even after controlling for age and AD pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/98-100\">",
"     98-100",
"    </a>",
"    ]. In one series, cortical microbleeds suggestive of CAA were identified by magnetic resonance imaging (MRI) in 65 percent of patients with vascular dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/101\">",
"     101",
"    </a>",
"    ]. Other studies found a correlation between the presence and number of lobar microbleeds with cognitive impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37001?source=see_link\">",
"     \"Cerebral amyloid angiopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cadasil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral autosomal dominant arteriopathy (CADASIL) is a disorder caused by mutations in the NOTCH3 gene on chromosome 19 that produces subcortical infarcts and leukoencephalopathy. Patients develop a subcortical VaD syndrome in the fifth to seventh decades. Other common features include migraine with aura and psychiatric symptoms. Pathology reveals extensive lacunar infarctions and white matter ischemia from occlusion of vessels by disease-specific granular material. The simultaneous prevalence of migraine, the absence of traditional atherosclerotic risk factors, and a history of multiple affected family members suggest this diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/6\">",
"     6",
"    </a>",
"    ]. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/16/11530?source=see_link\">",
"     \"Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mixed dementia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed dementia, or AD with cerebrovascular disease, refers to the co-occurrence of AD and VaD pathology and is increasingly recognized as a condition requiring independent consideration. It is often difficult to distinguish AD and VaD let alone determine which is etiologically most important when both pathologies are present.",
"   </p>",
"   <p>",
"    The high prevalence of both AD and VaD are such that their co-occurrence is common. In autopsy series, vascular pathology was found in 34 to 50 percent of those with pathologic AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/75,104-108\">",
"     75,104-108",
"    </a>",
"    ]. About one-third of patients diagnosed with VaD will have AD pathology at autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/106\">",
"     106",
"    </a>",
"    ]. Using the relatively loose definitions of pathologic criteria for AD and VaD, patients with clinical dementia are in fact more likely to have combined pathology rather than either AD or VaD in isolation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to their frequent coincidence, there is increasing evidence that AD and VaD may share etiologic or pathogenic features",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    influence each other's course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/109-111\">",
"     109-111",
"    </a>",
"    ]. In some studies, AD and VaD appear to share vascular risk factors including hypertension and hyperlipidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/112,113\">",
"     112,113",
"    </a>",
"    ] and possibly diabetes and smoking as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/114\">",
"     114",
"    </a>",
"    ]. A population-based cohort of 599 85-year-old individuals found that the baseline burden of generalized atherosclerosis was associated with cognitive decline over a five-year follow-up period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/115\">",
"     115",
"    </a>",
"    ]. In smaller cohorts of patients with AD, prevalent vascular risk factors, coronary artery disease,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    incident stroke have been variably associated with increased rates of cognitive decline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/116-118\">",
"     116-118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The apolipoprotein E epsilon 4 (ApoE e4) genotype has been associated with cardiovascular disease and with AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/104,119\">",
"     104,119",
"    </a>",
"    ]. In one autopsy study of 99 individuals, the severity of coronary artery disease was significantly associated with the density of AD neuropathologic features, primarily in ApoE e4 carriers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/120\">",
"     120",
"    </a>",
"    ]. In another autopsy series, ApoE e4 was associated with subcortical microvascular changes, but not gross cerebrovascular pathology, in patients with AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/121\">",
"     121",
"    </a>",
"    ]. The association of ApoE e4 with clinical VaD is uncertain; some studies have found an association and others not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/54,122-125\">",
"     54,122-125",
"    </a>",
"    ]. A large prospective study found that both stroke and ApoE e4 contributed to the risk of dementia, but the two risk factors appeared to be independent and did not interact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of clinical-neuropathologic studies suggest that in the setting of cerebrovascular disease, a smaller degree of AD pathology is required to produce dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/88,127-130\">",
"     88,127-130",
"    </a>",
"    ]. As an example, among the 61 patients in the Nun study who met neuropathologic criteria for AD, clinical dementia was more likely in patients with compared to those without infarctions (OR 20.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/127\">",
"     127",
"    </a>",
"    ]. Fewer neuropathologic lesions of AD appeared to result in dementia if infarction was present. One MRI study suggested that the hallmark findings of VaD (white matter lesions) and of AD (cerebral atrophy) appeared to have a synergistic effect on cognitive decline in patients with mild AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/131\">",
"     131",
"    </a>",
"    ]. Interpretation of this finding is complicated by the fact that white matter lesions are not specific to vascular damage and may represent Wallerian degeneration from neurodegeneration secondary to AD pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of studies have also associated cerebrovascular lesions with AD. From these and other studies, some conclude that a vascular mechanism may be a primary etiologic factor in AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic cervical carotid disease has also been associated with cognitive impairment independent of other vascular risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/134\">",
"       134",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An autopsy series of 10 AD patients and 10 nondemented controls of similar age and gender mix found that patients with AD had a significantly higher burden of atherosclerosis in both the circle of Willis and leptomeningeal arteries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/135\">",
"       135",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of large vessel atherosclerosis (but not cerebral infarction) was associated with an increased frequency of neuritic plaque but not neurofibrillary tangles in a study of 1054 autopsies from the US National Alzheimer's Coordinating Center [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/136\">",
"       136",
"      </a>",
"      ]. These findings suggest that atherosclerosis might lead to neuritic plaque formation by some pathway other than infarction, perhaps by directly influencing amyloid deposition.",
"     </li>",
"     <li>",
"      Sequential MRI scans performed in some AD patients suggest that the progression of periventricular white matter lesions is an important factor in disease progression and functional decline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/137,138\">",
"       137,138",
"      </a>",
"      ]. In contrast, a MRI study of 590 patients who met criteria for vascular dementia, the degree of medial temporal lobe atrophy (the hallmark MRI finding of AD) and the presence of large artery vessel lesions were the major determinants of cognitive impairment, while small vessel pathology was not an independent contributor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/139\">",
"       139",
"      </a>",
"      ] Other studies have also found that hippocampal atrophy is an important substrate for dementia in patients with cerebrovascular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/60\">",
"       60",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'White matter lesions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Among 148 autopsied subjects in the Rush Memory and Aging Project, after controlling for AD pathology, cerebral infarctions increased the odds of dementia fivefold and interacted with AD pathology to worsen memory function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/130\">",
"       130",
"      </a>",
"      ]. Another autopsy study of 43 patients with neuropathologically confirmed AD showed that the severity of both cortical microinfarcts and periventricular demyelination were associated with the clinical dementia rating scale score as assessed within three months of death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/129\">",
"       129",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these findings suggest an interaction between cerebrovascular disease and AD pathology, other studies suggest otherwise. Clinical neuropathologic correlation in 153 deceased clergy with and without dementia followed prospectively in life found that cerebral infarctions and AD pathology contributed independently in an additive fashion to the likelihood of dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/140\">",
"     140",
"    </a>",
"    ]. An examination of 79 autopsy cases derived from a longitudinal study of mixed dementia found that in advanced cases, AD pathology appeared to overwhelm cerebrovascular pathology as the major determinant of dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/107\">",
"     107",
"    </a>",
"    ]. Finally, in another study, while cardiovascular risk factors were associated with a decline in cognition and executive function, they were not associated with AD specific pathologic findings such as hippocampal atrophy or cerebrospinal fluid biomarkers of AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/141\">",
"     141",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the diverse pathologies, it is not surprising that the clinical manifestations of vascular dementia (VaD) are diverse. Clinicians and investigators have long recognized two clinical patterns - one in which the predominant pathology and clinical features are cortical and one in which they are subcortical [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/142\">",
"     142",
"    </a>",
"    ]. While in themselves heterogeneous, these two patterns nonetheless have distinct features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cortical syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In primarily cortical VaD, cognitive features are specific to the areas affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/142\">",
"     142",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medial frontal: executive dysfunction, abulia, or apathy. Bilateral medial frontal lobe infarction may cause akinetic mutism.",
"     </li>",
"     <li>",
"      Left parietal: aphasia, apraxia, or agnosia.",
"     </li>",
"     <li>",
"      Right parietal: hemineglect (anosognosia, asomatognosia), confusion, agitation, visuospatial and constructional difficulty.",
"     </li>",
"     <li>",
"      Medial temporal: anterograde amnesia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cortical branch occlusions are often caused by embolism from the heart or large arteries and may present with clinical stroke. However, when the superior division of the middle cerebral artery is not involved, hemiparesis may not be an obvious signal to its sudden appearance. Onset may appear more insidious as a result, and it is not uncommon for the patient to improve again before the next event. The course is thus often perceived as fluctuating or stepwise. As few as one-third of patients with multi-infarct dementia (MID) experience both an abrupt onset and stepwise deterioration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Subcortical syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In subcortical pathology, both lacunar infarctions and chronic ischemia affect the deep cerebral nuclei and white matter pathways. These often disrupt frontal lobe and other cortico-cortico circuits, producing deficits attributable to remote brain areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/95,142,144,145\">",
"     95,142,144,145",
"    </a>",
"    ]. Characteristic features include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Focal motor signs",
"     </li>",
"     <li>",
"      Early presence of gait disturbance (marche a petit pas or magnetic, apraxic gait or Parkinsonian gait)",
"     </li>",
"     <li>",
"      History of unsteadiness and frequent, unprovoked falls",
"     </li>",
"     <li>",
"      Early urinary frequency, urgency, and other urinary symptoms not explained by urologic disease",
"     </li>",
"     <li>",
"      Pseudobulbar palsy",
"     </li>",
"     <li>",
"      Personality and mood changes, abulia, apathy, depression, emotional incontinence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/146\">",
"       146",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cognitive disorder characterized by relatively mild memory deficit, psychomotor retardation, and abnormal executive function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/147\">",
"       147",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The course of subcortical VaD may be gradual or stepwise and either slow or fast in decline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial approach to a patient with evidence of cognitive decline is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    .) The specific approach in patients with suspected vascular dementia (VaD) is presented here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;While not essential in the evaluation of all patients with dementia, neuroimaging should be performed in patients with suspected VaD by virtue of stroke history, vascular risk factors, abnormal neurologic examination, or a course or symptom complex atypical for AD. MRI is significantly more sensitive than CT; however, if sufficient evidence of vascular pathology is seen on CT, an MRI may not be necessary. MRI will show the fundamental hallmarks of VaD including cortical and subcortical infarctions as well as the presence of subcortical ischemic changes or leukoaraiosis. However, radiographic criteria alone have been shown to be inadequate at differentiating between poststroke patients with and without dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/148\">",
"     148",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     White matter lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral white matter lesions (WML) or leukoaraiosis on brain MRI is a nonspecific radiologic finding. These changes are somewhat ubiquitous in the normal as well as the demented elderly population. Radiologic WML do not define a single neuropathology and are associated with nonvascular pathology including infections, demyelination, neoplasia, and metabolic disorders, making clinical correlation important.",
"   </p>",
"   <p>",
"    In elderly patients with vascular risk factors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vascular dementia (VaD), WML are believed to be related to cerebral hypoperfusion or ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/149\">",
"     149",
"    </a>",
"    ]. In this setting, pathological studies show rarefaction of the white matter (a reduction in axonal and myelin density) and perivascular gliosis rather than frank infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/72,150-152\">",
"     72,150-152",
"    </a>",
"    ]. A postmortem study of cerebral molecular pathology in elderly patients found that molecular markers of a hypoxic response, arteriolar sclerosis, and cerebral amyloid angiopathy were increased in WML compared with the normal white matter in these individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/153\">",
"     153",
"    </a>",
"    ]. Further evidence that these lesions have a vascular origin comes from another histopathologic study, which found that these lesions consistently demonstrate reduced CD31 staining, a marker of endothelial vascular integrity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/154\">",
"     154",
"    </a>",
"    ]. Also, in the Framingham offspring study, WML were associated with higher plasma levels of asymmetrical dimethylarginine (ADMA), an inhibitor of endothelial nitric oxide synthase and a marker of endothelial dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/155\">",
"     155",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of WML is significantly associated with age and hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/141,149,156-165\">",
"     141,149,156-165",
"    </a>",
"    ]. The burden of WML increases over time; age and hypertension are risk factors for disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/162,166-170\">",
"     162,166-170",
"    </a>",
"    ]. WML are more common in patients with ischemic stroke and are associated with the incidence of both silent and clinical infarctions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/156,167,171,172\">",
"     156,167,171,172",
"    </a>",
"    ]. Chronic kidney disease, metabolic syndrome, microvascular retinopathy, elevated homocysteine, lower vitamin B12 levels, and C reactive protein levels (and other inflammatory biomarkers) are also associated with WML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/173-182\">",
"     173-182",
"    </a>",
"    ]. The volume of WML has also been correlated with plasma A beta 40 levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/183,184\">",
"     183,184",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in siblings and twins suggest a genetic basis for the accumulation of WML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/185,186\">",
"     185,186",
"    </a>",
"    ]. These may reflect, in part, a genetic risk for cerebrovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/186-188\">",
"     186-188",
"    </a>",
"    ]. While some studies have reported associations between certain genetic loci and WML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/189-197\">",
"     189-197",
"    </a>",
"    ], a 2009 meta-analysis of the largest available studies concluded that no genetic polymorphism has yet shown convincing evidence for an association with WML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/198\">",
"     198",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have not consistently shown a relationship between the extent of WML and the presence of dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/86,199,200\">",
"     86,199,200",
"    </a>",
"    ]. There are several potential reasons for this including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Traditional definitions of dementia may be an insensitive measure of cognitive change in VaD. WML appear to more consistently affect subsets of cognition, in particular tests of executive control and other cognitive domains associated with frontal lobe systems [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/86,201-203\">",
"       86,201-203",
"      </a>",
"      ]. Supporting this is a study in 70 older adults that found that WML specifically predicted executive impairments and slowed processing speed, not performance on memory and naming tasks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/204\">",
"       204",
"      </a>",
"      ]. The fact that WML are more reliably associated with increased risk of cognitive decline and incident dementia, rather than prevalent dementia is also consistent with this hypothesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/55,73,144,205-210\">",
"       55,73,144,205-210",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Methods quantifying WML severity are inconsistent and often subjective. Rating scales based on visual assessment do not correlate well with computerized volumetric assessments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/211\">",
"       211",
"      </a>",
"      ]. Nonetheless, volumetric changes do indicate that the greater brain volume affected by such changes, the greater the risk of concurrent or future cognitive decline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/86,208,210,212\">",
"       86,208,210,212",
"      </a>",
"      ]. Some studies suggest that there may be a threshold effect for lesion volume in producing cognitive impairment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/86,213,214\">",
"       86,213,214",
"      </a>",
"      ]. The severity of WML has also been correlated with deficits in gait and motor function, clinical features of subcortical vascular dementia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/210,215-217\">",
"       210,215-217",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The anatomic distribution of WML may be more important than the total volume [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/138,218\">",
"       138,218",
"      </a>",
"      ]. Evidence from several, but not all studies indicates that cognitive impairment is better associated with periventricular rather than subcortical WML [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/144,161,171,204,207,219,220\">",
"       144,161,171,204,207,219,220",
"      </a>",
"      ]. This observation suggests that disruption of periventricular long association fibers connecting distant cortical regions causes greater cognitive impairment than disruption of subcortical association arcuate fibers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/207,221\">",
"       207,221",
"      </a>",
"      ]. The specific importance of pathology in this location to cognitive decline is supported by the observation that periventricular but not nonperiventricular WML are associated with lower cortical cholinergic activity as measured on positron emission tomography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/222\">",
"       222",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, the localization of hyperintensities in the periventricular versus subcortical white matter is, in many cases, an artifact of viewing images of the brain in the axial plane. On anatomic mapping, periventricular and deep white matter hyperintensities are highly correlated with each other and progressively larger total white matter hyperintensity volumes are associated with smooth extension from periventricular to subcortical areas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/223\">",
"       223",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Progression of WML may correlate better with VaD than a single measure of WML volume. Increasing white matter lesion burden on serial MRI scans has been associated with accelerated cognitive decline in several studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/166,168,170,210,224-227\">",
"       166,168,170,210,224-227",
"      </a>",
"      ]. Progression of WML is more likely, however, in patients with a higher baseline lesion load.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of clinical criteria have been published for the diagnosis of VaD. The earliest of these, the Hachinski Ischemic Score (HIS) (",
"    <a class=\"graphic graphic_table graphicRef81210 \" href=\"mobipreview.htm?30/24/31115\">",
"     table 1",
"    </a>",
"    ) is still used today and was established to distinguish multi-infarct dementia (MID) from AD rather than as independent diagnostic criteria for VaD. The HIS items highlight clinical features specific to VaD, such as stepwise deterioration, fluctuating course, hypertension, history of stroke, and focal neurologic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/228\">",
"     228",
"    </a>",
"    ]. Data from pathologically verified cases show that an HIS&ge;7 has a sensitivity and specificity of about 90 percent for VaD and good inter-rater reliability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/228\">",
"     228",
"    </a>",
"    ]. However, differentiating VaD from mixed dementia is a difficult problem with all the available criteria. This is no less true of the HIS, in which the specificity in separating either VaD or AD from mixed dementia has been found to be 17.2 and 29.4 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/228\">",
"     228",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are four widely used independent diagnostic criteria for VaD:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)",
"     </li>",
"     <li>",
"      State of California Alzheimer's Disease Diagnostic and Treatment Centers (ADDTC)",
"     </li>",
"     <li>",
"      National Institute for Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN)",
"     </li>",
"     <li>",
"      International Classification of Diseases, tenth edition (ICD-10)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The criteria vary by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How dementia is defined",
"     </li>",
"     <li>",
"      What types of CVD are included",
"     </li>",
"     <li>",
"      What other disorders must be specifically excluded",
"     </li>",
"     <li>",
"      Whether focal examination findings are required",
"     </li>",
"     <li>",
"      Whether the presence of vascular disease must be corroborated by neuroimaging",
"     </li>",
"     <li>",
"      Whether a temporal relationship between stroke event and cognitive decline is required",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The NINDS-AIREN criteria are the most detailed and most widely used (",
"    <a class=\"graphic graphic_table graphicRef67333 \" href=\"mobipreview.htm?11/5/11356\">",
"     table 2",
"    </a>",
"    ). In all but the ADDTC criteria, a memory disorder is a requirement in addition to the involvement of other cognitive domains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/229\">",
"     229",
"    </a>",
"    ]. Both",
"    <span class=\"nowrap\">",
"     NINDS/AIREN",
"    </span>",
"    and ADDTC rely on neuroimaging confirmation of cerebrovascular lesions and require a temporal association but not an anatomic association between",
"    <span class=\"nowrap\">",
"     cognitive/functional",
"    </span>",
"    decline and stroke event. A number of studies have shown that the different criteria do not identify the same patients, leading to variations in published prevalence and incidence estimates as well as treatment effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/228,230-235\">",
"     228,230-235",
"    </a>",
"    ]. As an example, in the assessment of 167 patients with probable dementia, the number of cases diagnosed with VaD were: DSM-IV = 45, ADDTC = 23, NINDS-AIREN = 12, and ICD-10 = 21 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/230\">",
"     230",
"    </a>",
"    ]. Only five cases met criteria for VaD using all four diagnostic tools.",
"   </p>",
"   <p>",
"    Overall, the HIS and DSM-IV criteria appear the most liberal in the identification of VaD and the NINDS-AIREN the most conservative. In addition, data suggest inter-rater reliability (kappa = 0.44 to 0.61) is only moderate for these criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/231\">",
"     231",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of its more distinctive and perhaps more uniform clinical profile, for which the above criteria may be insensitive, separate criteria for subcortical VaD have been proposed. This requires neuroimaging evidence of subcortical vascular pathology and a typical neuropsychiatric profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While necessary for research studies, clinical criteria that distinguish VaD from AD or mixed dementia seem less clinically imperative. In the evaluation of patients with dementia, it may be more important to identify a potential contribution from vascular pathology rather than to specifically diagnose VaD. The HIS is well suited for this purpose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Neuropsychological testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formal neuropsychological testing quantitates the degree of cognitive impairment and the domains involved in order to provide a baseline measurement to follow the course of disease and response to treatment.",
"   </p>",
"   <p>",
"    Testing can also help detect cognitive patterns suggestive of certain disorders such as VaD, AD, Lewy Body disease, and frontotemporal dementia. One review found that patients with VaD have similar deficits compared with AD patients (on tests of language, construction, and memory registration) but are significantly less impaired on tests of recognition memory and are more impaired on measures of executive functioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/236\">",
"     236",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Executive functioning is the ability to conceptualize all facets of an activity and translate that into appropriate and effective behavior; tests of this domain might include trail making and the digit symbol test, as well as bedside tasks such as the Luria \"fist-edge-palm\" test and the Go-No-Go task included in the Frontal Assessment Battery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/237,238\">",
"     237,238",
"    </a>",
"    ]. Deficits in this area are common to all dementias but are distinctive in VaD, in that measurable deficits often occur prior to the diagnosis of dementia, correlate best with neuroimaging findings, and cause most of the early impairments prior to the development of severe memory loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/239\">",
"     239",
"    </a>",
"    ]. These tenets have not been well validated with clinical neuropathologic studies. However, one small autopsy series found that predominant executive dysfunction was present in four of six patients with cognitive impairment attributed to cerebrovascular disease, with a sensitivity of 67 percent and a specificity of 86 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/57/37786/abstract/240\">",
"     240",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When attempting to distinguish static cognitive deficits after a stroke from dementia, serial neuropsychological testing, usually annually, is often invaluable. Deficits detected on neuropsychological tests can frequently be helpful clinically and guide decisions regarding independent living, safety restrictions, and the like.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Testing for underlying vascular pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;When cerebral infarction occurs or is identified on neuroimaging, evaluation to define a specific stroke subtype or etiology should be initiated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=see_link\">",
"     \"Overview of the evaluation of stroke\"",
"    </a>",
"    .) At a minimum, a typical patient with VaD should have carotid Doppler ultrasound or other carotid imaging if strokes in that territory have occurred. Work-up for cardiogenic emboli usually includes an echocardiogram and often a holter monitor. Patients should be screened for usual risk factors including hypertension, diabetes, and hyperlipidemia. These are recommended on the basis that such testing leads to effective preventative strategies for recurrent stroke, but this approach has not been shown to improve prognosis in patients with or at risk for VaD per se.",
"   </p>",
"   <p>",
"    Specific testing for the more unusual causes of stroke and VaD should be guided by specific circumstances that make these disorders suspect (an unusual situation). For patients with a history suggestive of CADASIL, a commercially available genetic test is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/37/14934?source=see_link\">",
"       \"Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While considerable uncertainty continues to surround vascular dementia (VaD), the following summarizes current understanding and offers some pragmatic suggestions for evaluation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presentation of cognitive impairment in VaD may be quite distinct from Alzheimer disease (AD), especially early in the disease course, with prominent deficits in executive dysfunction causing significant disability, even while memory impairment is quite mild and before the patient reaches criteria for dementia. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuropsychological testing can be helpful to better profile the nature and severity of the cognitive deficits and chart disease course in VaD. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Neuropsychological testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is considerable overlap between AD and VaD with regard to comorbidity as well as shared risk factors and even pathogenesis. The combination of pathologies may be more common than either in isolation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Mixed dementia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no uniform diagnostic criteria for VaD. Evidence of prominent executive dysfunction, a stroke history, vascular risk factors, and a high Hachinski Ischemic Score (",
"      <a class=\"graphic graphic_table graphicRef81210 \" href=\"mobipreview.htm?30/24/31115\">",
"       table 1",
"      </a>",
"      ) should suggest either the diagnosis of VaD or AD with cerebrovascular disease and prompt a neuroimaging study. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/1\">",
"      Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci 1970; 11:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/2\">",
"      Hachinski VC, Lassen NA, Marshall J. Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet 1974; 2:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/3\">",
"      Hachinski VC, Bowler JV. Vascular dementia. Neurology 1993; 43:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/4\">",
"      O'Brien JT, Erkinjuntti T, Reisberg B, et al. Vascular cognitive impairment. Lancet Neurol 2003; 2:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/5\">",
"      Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006; 37:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/6\">",
"      Rom&aacute;n GC, Sachdev P, Royall DR, et al. Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia. J Neurol Sci 2004; 226:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/7\">",
"      Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/8\">",
"      Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54:S10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/9\">",
"      Sonnen JA, Larson EB, Crane PK, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol 2007; 62:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/10\">",
"      Ikeda M, Hokoishi K, Maki N, et al. Increased prevalence of vascular dementia in Japan: a community-based epidemiological study. Neurology 2001; 57:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/11\">",
"      Ikejima C, Yasuno F, Mizukami K, et al. Prevalence and causes of early-onset dementia in Japan: a population-based study. Stroke 2009; 40:2709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/12\">",
"      H&eacute;bert R, Brayne C. Epidemiology of vascular dementia. Neuroepidemiology 1995; 14:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/13\">",
"      Rockwood K, Wentzel C, Hachinski V, et al. Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology 2000; 54:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/14\">",
"      H&eacute;bert R, Lindsay J, Verreault R, et al. Vascular dementia : incidence and risk factors in the Canadian study of health and aging. Stroke 2000; 31:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/15\">",
"      Fitzpatrick AL, Kuller LH, Ives DG, et al. Incidence and prevalence of dementia in the Cardiovascular Health Study. J Am Geriatr Soc 2004; 52:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/16\">",
"      Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. Neurology 1998; 51:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/17\">",
"      Kuller LH, Lopez OL, Jagust WJ, et al. Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology 2005; 64:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/18\">",
"      Andersen K, Launer LJ, Dewey ME, et al. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology 1999; 53:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/19\">",
"      Suryadevara V, Storey SG, Aronow WS, Ahn C. Association of abnormal serum lipids in elderly persons with atherosclerotic vascular disease and dementia, atherosclerotic vascular disease without dementia, dementia without atherosclerotic vascular disease, and no dementia or atherosclerotic vascular disease. J Gerontol A Biol Sci Med Sci 2003; 58:M859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/20\">",
"      Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004; 61:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/21\">",
"      Posner HB, Tang MX, Luchsinger J, et al. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 2002; 58:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/22\">",
"      Ross GW, Petrovitch H, White LR, et al. Characterization of risk factors for vascular dementia: the Honolulu-Asia Aging Study. Neurology 1999; 53:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/23\">",
"      Ott A, Stolk RP, Hofman A, et al. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996; 39:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/24\">",
"      Geroldi C, Frisoni GB, Paolisso G, et al. Insulin resistance in cognitive impairment: the InCHIANTI study. Arch Neurol 2005; 62:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/25\">",
"      Ahtiluoto S, Polvikoski T, Peltonen M, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 2010; 75:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/26\">",
"      Dichgans M, Zietemann V. Prevention of vascular cognitive impairment. Stroke 2012; 43:3137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/27\">",
"      Kalmijn S, Foley D, White L, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol 2000; 20:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/28\">",
"      Solfrizzi V, Scafato E, Capurso C, et al. Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing. J Neurol Neurosurg Psychiatry 2010; 81:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/29\">",
"      Segura B, Jurado MA, Freixenet N, et al. Mental slowness and executive dysfunctions in patients with metabolic syndrome. Neurosci Lett 2009; 462:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/30\">",
"      Ivan CS, Seshadri S, Beiser A, et al. Dementia after stroke: the Framingham Study. Stroke 2004; 35:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/31\">",
"      Desmond DW, Moroney JT, Sano M, Stern Y. Incidence of dementia after ischemic stroke: results of a longitudinal study. Stroke 2002; 33:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/32\">",
"      Altieri M, Di Piero V, Pasquini M, et al. Delayed poststroke dementia: a 4-year follow-up study. Neurology 2004; 62:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/33\">",
"      Lin JH, Lin RT, Tai CT, et al. Prediction of poststroke dementia. Neurology 2003; 61:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/34\">",
"      Censori B, Manara O, Agostinis C, et al. Dementia after first stroke. Stroke 1996; 27:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/35\">",
"      Inzitari D, Di Carlo A, Pracucci G, et al. Incidence and determinants of poststroke dementia as defined by an informant interview method in a hospital-based stroke registry. Stroke 1998; 29:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/36\">",
"      Pohjasvaara T, Erkinjuntti T, Ylikoski R, et al. Clinical determinants of poststroke dementia. Stroke 1998; 29:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/37\">",
"      Kokmen E, Whisnant JP, O'Fallon WM, et al. Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960-1984). Neurology 1996; 46:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/38\">",
"      Srikanth VK, Quinn SJ, Donnan GA, et al. Long-term cognitive transitions, rates of cognitive change, and predictors of incident dementia in a population-based first-ever stroke cohort. Stroke 2006; 37:2479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/39\">",
"      Leys D, H&eacute;non H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. Lancet Neurol 2005; 4:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/40\">",
"      Melkas S, Oksala NK, Jokinen H, et al. Poststroke dementia predicts poor survival in long-term follow-up: influence of prestroke cognitive decline and previous stroke. J Neurol Neurosurg Psychiatry 2009; 80:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/41\">",
"      Gottesman RF, Hillis AE. Predictors and assessment of cognitive dysfunction resulting from ischaemic stroke. Lancet Neurol 2010; 9:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/42\">",
"      B&eacute;jot Y, Aboa-Eboul&eacute; C, Durier J, et al. Prevalence of early dementia after first-ever stroke: a 24-year population-based study. Stroke 2011; 42:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/43\">",
"      Dong Y, Venketasubramanian N, Chan BP, et al. Brief screening tests during acute admission in patients with mild stroke are predictive of vascular cognitive impairment 3-6 months after stroke. J Neurol Neurosurg Psychiatry 2012; 83:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/44\">",
"      Jacova C, Pearce LA, Costello R, et al. Cognitive impairment in lacunar strokes: the SPS3 trial. Ann Neurol 2012; 72:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/45\">",
"      Snaphaan L, de Leeuw FE. Poststroke memory function in nondemented patients: a systematic review on frequency and neuroimaging correlates. Stroke 2007; 38:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/46\">",
"      Reitz C, Bos MJ, Hofman A, et al. Prestroke cognitive performance, incident stroke, and risk of dementia: the Rotterdam Study. Stroke 2008; 39:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/47\">",
"      Knopman DS, Roberts RO, Geda YE, et al. Association of prior stroke with cognitive function and cognitive impairment: a population-based study. Arch Neurol 2009; 66:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/48\">",
"      Frampton M, Harvey RJ, Kirchner V. Propentofylline for dementia. Cochrane Database Syst Rev 2003; :CD002853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/49\">",
"      Gamaldo A, Moghekar A, Kilada S, et al. Effect of a clinical stroke on the risk of dementia in a prospective cohort. Neurology 2006; 67:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/50\">",
"      Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 2009; 8:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/51\">",
"      Narasimhalu K, Ang S, De Silva DA, et al. Severity of CIND and MCI predict incidence of dementia in an ischemic stroke cohort. Neurology 2009; 73:1866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/52\">",
"      Savva GM, Stephan BC, Alzheimer's Society Vascular Dementia Systematic Review Group. Epidemiological studies of the effect of stroke on incident dementia: a systematic review. Stroke 2010; 41:e41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/53\">",
"      Elkins JS, Yaffe K, Cauley JA, et al. Pre-existing hypertension and the impact of stroke on cognitive function. Ann Neurol 2005; 58:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/54\">",
"      Rowan E, Morris CM, Stephens S, et al. Impact of hypertension and apolipoprotein E4 on poststroke cognition in subjects &gt;75 years of age. Stroke 2005; 36:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/55\">",
"      Jokinen H, Kalska H, M&auml;ntyl&auml; R, et al. White matter hyperintensities as a predictor of neuropsychological deficits post-stroke. J Neurol Neurosurg Psychiatry 2005; 76:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/56\">",
"      Luchsinger JA, Patel B, Tang MX, et al. Measures of adiposity and dementia risk in elderly persons. Arch Neurol 2007; 64:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/57\">",
"      Newman GC, Bang H, Hussain SI, Toole JF. Association of diabetes, homocysteine, and HDL with cognition and disability after stroke. Neurology 2007; 69:2054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/58\">",
"      Kwok CS, Loke YK, Hale R, et al. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology 2011; 76:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/59\">",
"      Firbank MJ, Allan LM, Burton EJ, et al. Neuroimaging predictors of death and dementia in a cohort of older stroke survivors. J Neurol Neurosurg Psychiatry 2012; 83:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/60\">",
"      Gemmell E, Bosomworth H, Allan L, et al. Hippocampal neuronal atrophy and cognitive function in delayed poststroke and aging-related dementias. Stroke 2012; 43:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/61\">",
"      Elkins JS, Longstreth WT Jr, Manolio TA, et al. Education and the cognitive decline associated with MRI-defined brain infarct. Neurology 2006; 67:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/62\">",
"      Ojala-Oksala J, Jokinen H, Kopsi V, et al. Educational history is an independent predictor of cognitive deficits and long-term survival in postacute patients with mild to moderate ischemic stroke. Stroke 2012; 43:2931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/63\">",
"      Wang Q, Capistrant BD, Ehntholt A, Glymour MM. Long-term rate of change in memory functioning before and after stroke onset. Stroke 2012; 43:2561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/64\">",
"      H&eacute;non H, Durieu I, Guerouaou D, et al. Poststroke dementia: incidence and relationship to prestroke cognitive decline. Neurology 2001; 57:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/65\">",
"      Serrano S, Domingo J, Rodr&iacute;guez-Garcia E, et al. Frequency of cognitive impairment without dementia in patients with stroke: a two-year follow-up study. Stroke 2007; 38:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/66\">",
"      Williamson JB, Nyenhuis DL, Pedelty L, et al. Baseline differences between vascular cognitive impairment no dementia reverters and non-reverters. J Neurol Neurosurg Psychiatry 2008; 79:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/67\">",
"      Ukraintseva S, Sloan F, Arbeev K, Yashin A. Increasing rates of dementia at time of declining mortality from stroke. Stroke 2006; 37:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/68\">",
"      Pasquini M, Leys D, Rousseaux M, et al. Influence of cognitive impairment on the institutionalisation rate 3 years after a stroke. J Neurol Neurosurg Psychiatry 2007; 78:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/69\">",
"      Oksala NK, Jokinen H, Melkas S, et al. Cognitive impairment predicts poststroke death in long-term follow-up. J Neurol Neurosurg Psychiatry 2009; 80:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/70\">",
"      Narasimhalu K, Ang S, De Silva DA, et al. The prognostic effects of poststroke cognitive impairment no dementia and domain-specific cognitive impairments in nondisabled ischemic stroke patients. Stroke 2011; 42:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/71\">",
"      Blum S, Luchsinger JA, Manly JJ, et al. Memory after silent stroke: hippocampus and infarcts both matter. Neurology 2012; 78:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/72\">",
"      Smith EE, Schneider JA, Wardlaw JM, Greenberg SM. Cerebral microinfarcts: the invisible lesions. Lancet Neurol 2012; 11:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/73\">",
"      Vermeer SE, Prins ND, den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/74\">",
"      Gold G, K&ouml;vari E, Herrmann FR, et al. Cognitive consequences of thalamic, basal ganglia, and deep white matter lacunes in brain aging and dementia. Stroke 2005; 36:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/75\">",
"      Kalaria RN. Cerebrovascular disease and mechanisms of cognitive impairment: evidence from clinicopathological studies in humans. Stroke 2012; 43:2526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/76\">",
"      Arvanitakis Z, Leurgans SE, Barnes LL, et al. Microinfarct pathology, dementia, and cognitive systems. Stroke 2011; 42:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/77\">",
"      Chui H. Vascular dementia, a new beginning: shifting focus from clinical phenotype to ischemic brain injury. Neurol Clin 2000; 18:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/78\">",
"      Rost NS, Rahman RM, Biffi A, et al. White matter hyperintensity volume is increased in small vessel stroke subtypes. Neurology 2010; 75:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/79\">",
"      Qiu C, Cotch MF, Sigurdsson S, et al. Cerebral microbleeds, retinopathy, and dementia: the AGES-Reykjavik Study. Neurology 2010; 75:2221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/80\">",
"      van Es AC, van der Grond J, de Craen AJ, et al. Cerebral microbleeds and cognitive functioning in the PROSPER study. Neurology 2011; 77:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/81\">",
"      Yakushiji Y, Noguchi T, Hara M, et al. Distributional impact of brain microbleeds on global cognitive function in adults without neurological disorder. Stroke 2012; 43:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/82\">",
"      Wardlaw JM, Doubal F, Armitage P, et al. Lacunar stroke is associated with diffuse blood-brain barrier dysfunction. Ann Neurol 2009; 65:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/83\">",
"      Topakian R, Barrick TR, Howe FA, Markus HS. Blood-brain barrier permeability is increased in normal-appearing white matter in patients with lacunar stroke and leucoaraiosis. J Neurol Neurosurg Psychiatry 2010; 81:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/84\">",
"      Swartz RH, Stuss DT, Gao F, Black SE. Independent cognitive effects of atrophy and diffuse subcortical and thalamico-cortical cerebrovascular disease in dementia. Stroke 2008; 39:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/85\">",
"      Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001; 357:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/86\">",
"      Wright CB, Festa JR, Paik MC, et al. White matter hyperintensities and subclinical infarction: associations with psychomotor speed and cognitive flexibility. Stroke 2008; 39:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/87\">",
"      Launer LJ, Hughes TM, White LR. Microinfarcts, brain atrophy, and cognitive function: the Honolulu Asia Aging Study Autopsy Study. Ann Neurol 2011; 70:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/88\">",
"      Troncoso JC, Zonderman AB, Resnick SM, et al. Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Ann Neurol 2008; 64:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/89\">",
"      Hulette C, Nochlin D, McKeel D, et al. Clinical-neuropathologic findings in multi-infarct dementia: a report of six autopsied cases. Neurology 1997; 48:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/90\">",
"      Erkinjuntti T, Inzitari D, Pantoni L, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000; 59:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/91\">",
"      Swartz RH, Black SE. Anterior-medial thalamic lesions in dementia: frequent, and volume dependently associated with sudden cognitive decline. J Neurol Neurosurg Psychiatry 2006; 77:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/92\">",
"      Gold G, Giannakopoulos P, Herrmann FR, et al. Identification of Alzheimer and vascular lesion thresholds for mixed dementia. Brain 2007; 130:2830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/93\">",
"      Benisty S, Gouw AA, Porcher R, et al. Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS study. J Neurol Neurosurg Psychiatry 2009; 80:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/94\">",
"      Stebbins GT, Nyenhuis DL, Wang C, et al. Gray matter atrophy in patients with ischemic stroke with cognitive impairment. Stroke 2008; 39:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/95\">",
"      Tatemichi TK, Desmond DW, Prohovnik I, et al. Confusion and memory loss from capsular genu infarction: a thalamocortical disconnection syndrome? Neurology 1992; 42:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/96\">",
"      Rockwood K, Ebly E, Hachinski V, Hogan D. Presence and treatment of vascular risk factors in patients with vascular cognitive impairment. Arch Neurol 1997; 54:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/97\">",
"      Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000; 356:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/98\">",
"      Greenberg SM, Gurol ME, Rosand J, Smith EE. Amyloid angiopathy-related vascular cognitive impairment. Stroke 2004; 35:2616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/99\">",
"      Greenberg SM, Vonsattel JP, Stakes JW, et al. The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage. Neurology 1993; 43:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/100\">",
"      Gray F, Dubas F, Roullet E, Escourolle R. Leukoencephalopathy in diffuse hemorrhagic cerebral amyloid angiopathy. Ann Neurol 1985; 18:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/101\">",
"      Cordonnier C, van der Flier WM, Sluimer JD, et al. Prevalence and severity of microbleeds in a memory clinic setting. Neurology 2006; 66:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/102\">",
"      van Norden AG, van den Berg HA, de Laat KF, et al. Frontal and temporal microbleeds are related to cognitive function: the Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Cohort (RUN DMC) Study. Stroke 2011; 42:3382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/103\">",
"      Poels MM, Ikram MA, van der Lugt A, et al. Cerebral microbleeds are associated with worse cognitive function: the Rotterdam Scan Study. Neurology 2012; 78:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/104\">",
"      Langa KM, Foster NL, Larson EB. Mixed dementia: emerging concepts and therapeutic implications. JAMA 2004; 292:2901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/105\">",
"      Massoud F, Devi G, Stern Y, et al. A clinicopathological comparison of community-based and clinic-based cohorts of patients with dementia. Arch Neurol 1999; 56:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/106\">",
"      Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999; 13 Suppl 3:S115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/107\">",
"      Chui HC, Zarow C, Mack WJ, et al. Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Ann Neurol 2006; 60:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/108\">",
"      Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/109\">",
"      Benarroch EE. Neurovascular unit dysfunction: a vascular component of Alzheimer disease? Neurology 2007; 68:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/110\">",
"      Firbank MJ, He J, Blamire AM, et al. Cerebral blood flow by arterial spin labeling in poststroke dementia. Neurology 2011; 76:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/111\">",
"      Jokinen H, Lipsanen J, Schmidt R, et al. Brain atrophy accelerates cognitive decline in cerebral small vessel disease: the LADIS study. Neurology 2012; 78:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/112\">",
"      Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/113\">",
"      Gorelick PB. Risk factors for vascular dementia and Alzheimer disease. Stroke 2004; 35:2620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/114\">",
"      Luchsinger JA, Reitz C, Honig LS, et al. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005; 65:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/115\">",
"      Vinkers DJ, Stek ML, van der Mast RC, et al. Generalized atherosclerosis, cognitive decline, and depressive symptoms in old age. Neurology 2005; 65:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/116\">",
"      Regan C, Katona C, Walker Z, et al. Relationship of vascular risk to the progression of Alzheimer disease. Neurology 2006; 67:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/117\">",
"      Mielke MM, Rosenberg PB, Tschanz J, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology 2007; 69:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/118\">",
"      Helzner EP, Luchsinger JA, Scarmeas N, et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 2009; 66:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/119\">",
"      Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004; 141:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/120\">",
"      Beeri MS, Rapp M, Silverman JM, et al. Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology 2006; 66:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/121\">",
"      Yip AG, McKee AC, Green RC, et al. APOE, vascular pathology, and the AD brain. Neurology 2005; 65:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/122\">",
"      Hsiung GY, Sadovnick AD, Feldman H. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. CMAJ 2004; 171:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/123\">",
"      Frikke-Schmidt R, Nordestgaard BG, Thudium D, et al. APOE genotype predicts AD and other dementia but not ischemic cerebrovascular disease. Neurology 2001; 56:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/124\">",
"      Slooter AJ, Cruts M, Hofman A, et al. The impact of APOE on myocardial infarction, stroke, and dementia: the Rotterdam Study. Neurology 2004; 62:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/125\">",
"      Godin O, Tzourio C, Maillard P, et al. Apolipoprotein E genotype is related to progression of white matter lesion load. Stroke 2009; 40:3186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/126\">",
"      Jin YP, &Oslash;stbye T, Feightner JW, et al. Joint effect of stroke and APOE 4 on dementia risk: the Canadian Study of Health and Aging. Neurology 2008; 70:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/127\">",
"      Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/128\">",
"      Riekse RG, Leverenz JB, McCormick W, et al. Effect of vascular lesions on cognition in Alzheimer's disease: a community-based study. J Am Geriatr Soc 2004; 52:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/129\">",
"      K&ouml;vari E, Gold G, Herrmann FR, et al. Cortical microinfarcts and demyelination affect cognition in cases at high risk for dementia. Neurology 2007; 68:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/130\">",
"      Schneider JA, Boyle PA, Arvanitakis Z, et al. Subcortical infarcts, Alzheimer's disease pathology, and memory function in older persons. Ann Neurol 2007; 62:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/131\">",
"      Brickman AM, Honig LS, Scarmeas N, et al. Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch Neurol 2008; 65:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/132\">",
"      Xie S, Xiao JX, Gong GL, et al. Voxel-based detection of white matter abnormalities in mild Alzheimer disease. Neurology 2006; 66:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/133\">",
"      de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002; 33:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/134\">",
"      Johnston SC, O'Meara ES, Manolio TA, et al. Cognitive impairment and decline are associated with carotid artery disease in patients without clinically evident cerebrovascular disease. Ann Intern Med 2004; 140:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/135\">",
"      Roher AE, Esh C, Rahman A, et al. Atherosclerosis of cerebral arteries in Alzheimer disease. Stroke 2004; 35:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/136\">",
"      Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology 2005; 64:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/137\">",
"      de Leeuw FE, Korf E, Barkhof F, Scheltens P. White matter lesions are associated with progression of medial temporal lobe atrophy in Alzheimer disease. Stroke 2006; 37:2248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/138\">",
"      Behl P, Bocti C, Swartz RH, et al. Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients. Arch Neurol 2007; 64:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/139\">",
"      Bastos-Leite AJ, van der Flier WM, van Straaten EC, et al. The contribution of medial temporal lobe atrophy and vascular pathology to cognitive impairment in vascular dementia. Stroke 2007; 38:3182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/140\">",
"      Schneider JA, Wilson RS, Bienias JL, et al. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 2004; 62:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/141\">",
"      Lo RY, Jagust WJ, Alzheimer's Disease Neuroimaging Initiative. Vascular burden and Alzheimer disease pathologic progression. Neurology 2012; 79:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/142\">",
"      Staekenborg SS, van der Flier WM, van Straaten EC, et al. Neurological signs in relation to type of cerebrovascular disease in vascular dementia. Stroke 2008; 39:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/143\">",
"      Fischer P, Gatterer G, Marterer A, et al. Course characteristics in the differentiation of dementia of the Alzheimer type and multi-infarct dementia. Acta Psychiatr Scand 1990; 81:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/144\">",
"      de Groot JC, de Leeuw FE, Oudkerk M, et al. Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol 2000; 47:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/145\">",
"      Mok V, Wong KK, Xiong Y, et al. Cortical and frontal atrophy are associated with cognitive impairment in age-related confluent white-matter lesion. J Neurol Neurosurg Psychiatry 2011; 82:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/146\">",
"      Staekenborg SS, Su T, van Straaten EC, et al. Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease. J Neurol Neurosurg Psychiatry 2010; 81:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/147\">",
"      Jokinen H, Kalska H, M&auml;ntyl&auml; R, et al. Cognitive profile of subcortical ischaemic vascular disease. J Neurol Neurosurg Psychiatry 2006; 77:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/148\">",
"      Ballard CG, Burton EJ, Barber R, et al. NINDS AIREN neuroimaging criteria do not distinguish stroke patients with and without dementia. Neurology 2004; 63:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/149\">",
"      Liao D, Cooper L, Cai J, et al. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. The ARIC Study. Atherosclerosis Risk in Communities Study. Stroke 1996; 27:2262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/150\">",
"      Chimowitz MI, Estes ML, Furlan AJ, Awad IA. Further observations on the pathology of subcortical lesions identified on magnetic resonance imaging. Arch Neurol 1992; 49:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/151\">",
"      van Swieten JC, van den Hout JH, van Ketel BA, et al. Periventricular lesions in the white matter on magnetic resonance imaging in the elderly. A morphometric correlation with arteriolosclerosis and dilated perivascular spaces. Brain 1991; 114 ( Pt 2):761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/152\">",
"      Gouw AA, Seewann A, Vrenken H, et al. Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. Brain 2008; 131:3286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/153\">",
"      Fernando MS, Simpson JE, Matthews F, et al. White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke 2006; 37:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/154\">",
"      Young VG, Halliday GM, Kril JJ. Neuropathologic correlates of white matter hyperintensities. Neurology 2008; 71:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/155\">",
"      Pikula A, B&ouml;ger RH, Beiser AS, et al. Association of plasma ADMA levels with MRI markers of vascular brain injury: Framingham offspring study. Stroke 2009; 40:2959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/156\">",
"      Longstreth WT Jr, Manolio TA, Arnold A, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke 1996; 27:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/157\">",
"      de Leeuw FE, de Groot JC, Oudkerk M, et al. A follow-up study of blood pressure and cerebral white matter lesions. Ann Neurol 1999; 46:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/158\">",
"      Dufouil C, de Kersaint-Gilly A, Besan&ccedil;on V, et al. Longitudinal study of blood pressure and white matter hyperintensities: the EVA MRI Cohort. Neurology 2001; 56:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/159\">",
"      van Dijk EJ, Breteler MM, Schmidt R, et al. The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension 2004; 44:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/160\">",
"      Goldstein IB, Bartzokis G, Guthrie D, Shapiro D. Ambulatory blood pressure and the brain: a 5-year follow-up. Neurology 2005; 64:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/161\">",
"      Yoshita M, Fletcher E, Harvey D, et al. Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology 2006; 67:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/162\">",
"      Sachdev P, Wen W, Chen X, Brodaty H. Progression of white matter hyperintensities in elderly individuals over 3 years. Neurology 2007; 68:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/163\">",
"      Godin O, Tzourio C, Maillard P, et al. Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: the Three-City (3C)-Dijon Magnetic Resonance Imaging Study. Circulation 2011; 123:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/164\">",
"      White WB, Wolfson L, Wakefield DB, et al. Average daily blood pressure, not office blood pressure, is associated with progression of cerebrovascular disease and cognitive decline in older people. Circulation 2011; 124:2312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/165\">",
"      Maillard P, Seshadri S, Beiser A, et al. Effects of systolic blood pressure on white-matter integrity in young adults in the Framingham Heart Study: a cross-sectional study. Lancet Neurol 2012; 11:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/166\">",
"      Schmidt R, Petrovic K, Ropele S, et al. Progression of leukoaraiosis and cognition. Stroke 2007; 38:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/167\">",
"      Gouw AA, van der Flier WM, Fazekas F, et al. Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke 2008; 39:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/168\">",
"      van Dijk EJ, Prins ND, Vrooman HA, et al. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study. Stroke 2008; 39:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/169\">",
"      Gottesman RF, Coresh J, Catellier DJ, et al. Blood pressure and white-matter disease progression in a biethnic cohort: Atherosclerosis Risk in Communities (ARIC) study. Stroke 2010; 41:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/170\">",
"      Maillard P, Carmichael O, Fletcher E, et al. Coevolution of white matter hyperintensities and cognition in the elderly. Neurology 2012; 79:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/171\">",
"      Wen W, Sachdev PS. Extent and distribution of white matter hyperintensities in stroke patients: the Sydney Stroke Study. Stroke 2004; 35:2813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/172\">",
"      Vermeer SE, Hollander M, van Dijk EJ, et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003; 34:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/173\">",
"      Wright CB, Paik MC, Brown TR, et al. Total homocysteine is associated with white matter hyperintensity volume: the Northern Manhattan Study. Stroke 2005; 36:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/174\">",
"      van Dijk EJ, Prins ND, Vermeer SE, et al. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation 2005; 112:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/175\">",
"      Wong TY, Klein R, Sharrett AR, et al. Cerebral white matter lesions, retinopathy, and incident clinical stroke. JAMA 2002; 288:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/176\">",
"      Khatri M, Wright CB, Nickolas TL, et al. Chronic kidney disease is associated with white matter hyperintensity volume: the Northern Manhattan Study (NOMAS). Stroke 2007; 38:3121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/177\">",
"      Park K, Yasuda N, Toyonaga S, et al. Significant association between leukoaraiosis and metabolic syndrome in healthy subjects. Neurology 2007; 69:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/178\">",
"      Barzilay JI, Fitzpatrick AL, Luchsinger J, et al. Albuminuria and dementia in the elderly: a community study. Am J Kidney Dis 2008; 52:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/179\">",
"      de Lau LM, Smith AD, Refsum H, et al. Plasma vitamin B12 status and cerebral white-matter lesions. J Neurol Neurosurg Psychiatry 2009; 80:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/180\">",
"      Pieters B, Staals J, Knottnerus I, et al. Periventricular white matter lucencies relate to low vitamin B12 levels in patients with small vessel stroke. Stroke 2009; 40:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/181\">",
"      Wright CB, Moon Y, Paik MC, et al. Inflammatory biomarkers of vascular risk as correlates of leukoariosis. Stroke 2009; 40:3466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/182\">",
"      Satizabal CL, Zhu YC, Mazoyer B, et al. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study. Neurology 2012; 78:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/183\">",
"      Gurol ME, Irizarry MC, Smith EE, et al. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 2006; 66:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/184\">",
"      Gomis M, Sobrino T, Ois A, et al. Plasma beta-amyloid 1-40 is associated with the diffuse small vessel disease subtype. Stroke 2009; 40:3197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/185\">",
"      Carmelli D, DeCarli C, Swan GE, et al. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke 1998; 29:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/186\">",
"      Turner ST, Jack CR, Fornage M, et al. Heritability of leukoaraiosis in hypertensive sibships. Hypertension 2004; 43:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/187\">",
"      Atwood LD, Wolf PA, Heard-Costa NL, et al. Genetic variation in white matter hyperintensity volume in the Framingham Study. Stroke 2004; 35:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/188\">",
"      Reed T, Kirkwood SC, DeCarli C, et al. Relationship of family history scores for stroke and hypertension to quantitative measures of white-matter hyperintensities and stroke volume in elderly males. Neuroepidemiology 2000; 19:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/189\">",
"      DeStefano AL, Atwood LD, Massaro JM, et al. Genome-wide scan for white matter hyperintensity: the Framingham Heart Study. Stroke 2006; 37:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/190\">",
"      de Leeuw FE, Richard F, de Groot JC, et al. Interaction between hypertension, apoE, and cerebral white matter lesions. Stroke 2004; 35:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/191\">",
"      Lemmens R, G&ouml;rner A, Schrooten M, Thijs V. Association of apolipoprotein E epsilon2 with white matter disease but not with microbleeds. Stroke 2007; 38:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/192\">",
"      Henskens LH, Kroon AA, van Boxtel MP, et al. Associations of the angiotensin II type 1 receptor A1166C and the endothelial NO synthase G894T gene polymorphisms with silent subcortical white matter lesions in essential hypertension. Stroke 2005; 36:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/193\">",
"      van Oijen M, Cheung EY, Geluk CE, et al. Haplotypes of the fibrinogen gene and cerebral small vessel disease: the Rotterdam scan study. J Neurol Neurosurg Psychiatry 2008; 79:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/194\">",
"      Turner ST, Fornage M, Jack CR Jr, et al. Genomic susceptibility Loci for brain atrophy, ventricular volume, and leukoaraiosis in hypertensive sibships. Arch Neurol 2009; 66:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/195\">",
"      Kochunov P, Glahn D, Winkler A, et al. Analysis of genetic variability and whole genome linkage of whole-brain, subcortical, and ependymal hyperintense white matter volume. Stroke 2009; 40:3685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/196\">",
"      Kochunov P, Glahn D, Lancaster J, et al. Whole brain and regional hyperintense white matter volume and blood pressure: overlap of genetic loci produced by bivariate, whole-genome linkage analyses. Stroke 2010; 41:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/197\">",
"      Fornage M, Debette S, Bis JC, et al. Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol 2011; 69:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/198\">",
"      Paternoster L, Chen W, Sudlow CL. Genetic determinants of white matter hyperintensities on brain scans: a systematic assessment of 19 candidate gene polymorphisms in 46 studies in 19,000 subjects. Stroke 2009; 40:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/199\">",
"      Verdelho A, Madureira S, Ferro JM, et al. Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. J Neurol Neurosurg Psychiatry 2007; 78:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/200\">",
"      Verdelho A, Madureira S, Moleiro C, et al. White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. Neurology 2010; 75:160.",
"     </a>",
"    </li>",
"    <li>",
"     Libon, DJ, Scheinthal, S, Penney, DL, et al. The neuropsychological differentiaion between Alzheimer's disease and subcortical vascular dementia. In: Current Clinical Neurology, Vascular Dementia: Cerebrovascular Mechanisms and Current Management, Humana Press, Totowa NJ 2005. p.281.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/202\">",
"      Au R, Massaro JM, Wolf PA, et al. Association of white matter hyperintensity volume with decreased cognitive functioning: the Framingham Heart Study. Arch Neurol 2006; 63:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/203\">",
"      Carey CL, Kramer JH, Josephson SA, et al. Subcortical lacunes are associated with executive dysfunction in cognitively normal elderly. Stroke 2008; 39:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/204\">",
"      Delano-Wood L, Abeles N, Sacco JM, et al. Regional white matter pathology in mild cognitive impairment: differential influence of lesion type on neuropsychological functioning. Stroke 2008; 39:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/205\">",
"      de Leeuw FE, de Groot JC, Achten E, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001; 70:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/206\">",
"      Schmidt R, Enzinger C, Ropele S, et al. Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet 2003; 361:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/207\">",
"      Prins ND, van Dijk EJ, den Heijer T, et al. Cerebral white matter lesions and the risk of dementia. Arch Neurol 2004; 61:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/208\">",
"      Inzitari D, Simoni M, Pracucci G, et al. Risk of rapid global functional decline in elderly patients with severe cerebral age-related white matter changes: the LADIS study. Arch Intern Med 2007; 167:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/209\">",
"      Smith EE, Egorova S, Blacker D, et al. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Arch Neurol 2008; 65:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/210\">",
"      Silbert LC, Nelson C, Howieson DB, et al. Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline. Neurology 2008; 71:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/211\">",
"      van Straaten EC, Fazekas F, Rostrup E, et al. Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study. Stroke 2006; 37:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/212\">",
"      Mosley TH Jr, Knopman DS, Catellier DJ, et al. Cerebral MRI findings and cognitive functioning: the Atherosclerosis Risk in Communities study. Neurology 2005; 64:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/213\">",
"      Libon DJ, Price CC, Giovannetti T, et al. Linking MRI hyperintensities with patterns of neuropsychological impairment: evidence for a threshold effect. Stroke 2008; 39:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/214\">",
"      Price CC, Mitchell SM, Brumback B, et al. MRI-leukoaraiosis thresholds and the phenotypic expression of dementia. Neurology 2012; 79:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/215\">",
"      Baezner H, Blahak C, Poggesi A, et al. Association of gait and balance disorders with age-related white matter changes: the LADIS study. Neurology 2008; 70:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/216\">",
"      Soumar&eacute; A, Elbaz A, Zhu Y, et al. White matter lesions volume and motor performances in the elderly. Ann Neurol 2009; 65:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/217\">",
"      Blahak C, Baezner H, Pantoni L, et al. Deep frontal and periventricular age related white matter changes but not basal ganglia and infratentorial hyperintensities are associated with falls: cross sectional results from the LADIS study. J Neurol Neurosurg Psychiatry 2009; 80:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/218\">",
"      Smith EE, Salat DH, Jeng J, et al. Correlations between MRI white matter lesion location and executive function and episodic memory. Neurology 2011; 76:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/219\">",
"      O'Brien JT, Ames D. White matter lesions in depression and Alzheimer's disease. Br J Psychiatry 1996; 169:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/220\">",
"      Koo BB, Bergethon P, Qiu WQ, et al. Clinical prediction of fall risk and white matter abnormalities: a diffusion tensor imaging study. Arch Neurol 2012; 69:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/221\">",
"      Smith EE, Gurol ME, Eng JA, et al. White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage. Neurology 2004; 63:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/222\">",
"      Bohnen NI, M&uuml;ller ML, Kuwabara H, et al. Age-associated leukoaraiosis and cortical cholinergic deafferentation. Neurology 2009; 72:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/223\">",
"      DeCarli C, Fletcher E, Ramey V, et al. Anatomical mapping of white matter hyperintensities (WMH): exploring the relationships between periventricular WMH, deep WMH, and total WMH burden. Stroke 2005; 36:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/224\">",
"      Longstreth WT Jr, Arnold AM, Beauchamp NJ Jr, et al. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 2005; 36:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/225\">",
"      Dufouil C, Godin O, Chalmers J, et al. Severe cerebral white matter hyperintensities predict severe cognitive decline in patients with cerebrovascular disease history. Stroke 2009; 40:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/226\">",
"      Silbert LC, Howieson DB, Dodge H, Kaye JA. Cognitive impairment risk: white matter hyperintensity progression matters. Neurology 2009; 73:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/227\">",
"      Jokinen H, Gouw AA, Madureira S, et al. Incident lacunes influence cognitive decline: the LADIS study. Neurology 2011; 76:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/228\">",
"      Moroney JT, Bagiella E, Desmond DW, et al. Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology 1997; 49:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/229\">",
"      Rom&aacute;n GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/230\">",
"      Wetterling T, Kanitz RD, Borgis KJ. Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke 1996; 27:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/231\">",
"      Chui HC, Mack W, Jackson JE, et al. Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. Arch Neurol 2000; 57:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/232\">",
"      Lopez OL, Kuller LH, Becker JT, et al. Classification of vascular dementia in the Cardiovascular Health Study Cognition Study. Neurology 2005; 64:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/233\">",
"      Pohjasvaara T, M&auml;ntyl&auml; R, Ylikoski R, et al. Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences. Stroke 2000; 31:2952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/234\">",
"      Gold G, Giannakopoulos P, Montes-Paixao J&uacute;nior C, et al. Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia. Neurology 1997; 49:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/235\">",
"      Holmes C, Cairns N, Lantos P, Mann A. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 1999; 174:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/236\">",
"      Looi JC, Sachdev PS. Differentiation of vascular dementia from AD on neuropsychological tests. Neurology 1999; 53:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/237\">",
"      O'Sullivan M, Morris RG, Markus HS. Brief cognitive assessment for patients with cerebral small vessel disease. J Neurol Neurosurg Psychiatry 2005; 76:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/238\">",
"      Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000; 55:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/239\">",
"      Price CC, Jefferson AL, Merino JG, et al. Subcortical vascular dementia: integrating neuropsychological and neuroradiologic data. Neurology 2005; 65:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/57/37786/abstract/240\">",
"      Reed BR, Mungas DM, Kramer JH, et al. Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease. Brain 2007; 130:731.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5085 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-DB96A30595-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_57_37786=[""].join("\n");
var outline_f36_57_37786=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Poststroke dementia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5885880\">",
"      - Clinical stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Subclinical \"silent\" brain infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ETIOLOGY AND PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RELATED CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cerebral amyloid angiopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cadasil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mixed dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cortical syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Subcortical syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - White matter lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Neuropsychological testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Testing for underlying vascular pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5085\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5085|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/24/31115\" title=\"table 1\">",
"      Hachinski ischemic score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/5/11356\" title=\"table 2\">",
"      Criteria for probable VaD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37001?source=related_link\">",
"      Cerebral amyloid angiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/16/11530?source=related_link\">",
"      Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/59/4026?source=related_link\">",
"      Lacunar infarcts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/37/14934?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10104?source=related_link\">",
"      Treatment and prevention of vascular dementia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_57_37787="HER-2 overexpress primary mets";
var content_f36_57_37787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Discordance in HER2 overexpression in primary breast tumors and distant metastases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author; year",
"       </td>",
"       <td class=\"subtitle1\">",
"        n",
"       </td>",
"       <td class=\"subtitle1\">",
"        Discordance in HER2 expression between primary and metastasis, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Method for assessing HER2 overexpression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Edgerton SE; 2000",
"       </td>",
"       <td>",
"        193",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        IHC + FISH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Masood M; 2000",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        IHC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gancberg D; 2002",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        IHC + FISH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dowsett M; 2003",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        IHC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Luftner D; 2004",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        IHC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zidan J; 2005",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        IHC + FISH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guarnieri V; 2008",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        IHC + FISH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fabi A; 2011",
"       </td>",
"       <td>",
"        137",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        IHC + FISH",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IHC: immunohistochemistry; FISH: fluorescence in situ hybridization.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_57_37787=[""].join("\n");
var outline_f36_57_37787=null;
var title_f36_57_37788="Pediatric ambulance equipment for basic life support";
var content_f36_57_37788=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pediatric equipment for basic life support (BLS) ambulances in the United States",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       BLS ambulances",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Required*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Airway and ventilation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Portable and fixed suction with regulator and wide bore suction tubing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Suction catheters: tonsil-tip and flexible (1 flexible between 6 and 10 F, 1 between 10 F and 16 F)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Fixed and portable metered flow oxygen and oxygen tubing with variable flow regulator",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Oxygen masks (valveless and nonrebreathing): adult and child sizes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Nasal cannulas: adult and child sizes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Bag-valve-mask resuscitator: hand operated, self-reexpanding bag for adult (&ge;1000 mL) and child (450-750 mL) with oxygen reservoir/accumulator, valve, and mask (neonatal, infant, child, and adult sizes)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Airways: oropharyngeal (sizes 0-5); nasopharyngeal (16 F-34 F, adult and child sizes)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Pulse oximeter with pediatric and adult probes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Saline drops and infant nasal bulb syringe",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Monitoring and defibrillation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Automatic external defibrillator with adult and pediatric pads and cables",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Immobilization devices",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Rigid cervical collars for children aged 2 years or older",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Head immobilization device, eg, firm padding or commercial device (not sand bags)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Lower extremity (femur) traction devices",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Upper and lower extremity immobilization devices for children",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Backboards",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Obstetrical kit",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Optional basic pediatric equipment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infant oxygen mask",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infant self-inflating resuscitation bag",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infant airways (nasopharyngeal 12 F, 14 F; oropharyngeal size 00)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       BP cuffs, neonatal and infant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Pediatric stethoscope",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     F: French.",
"     <br>",
"      * In addition to standard equipment and supplies as determined by state and local regulations.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Policy statement--Equipment for ambulances. American College of Surgeons Committee on Trauma, American College of Emergency Physicians, National Association of EMS Physicians, Pediatric Equipment Guidelines Committee - Emergency Medical Services for Children (EMSC) Partnership for Children Stakeholder Group, American Academy of Pediatrics. Pediatrics 2009; 124:e166.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_57_37788=[""].join("\n");
var outline_f36_57_37788=null;
var title_f36_57_37789="Frequency of retained placenta by gestational age";
var content_f36_57_37789=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Rate of retained placenta by gestational age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 354px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retained placenta rate at different gestational ages.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Dombrowski, MP, Bottoms, SF, Saleh, AA, et al. Third stage of labor: analysis of duration and clinical practice. Am J Obstet Gynecol 1995; 172:1279.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_57_37789=[""].join("\n");
var outline_f36_57_37789=null;
var title_f36_57_37790="Nerve toxicity of organophosphates and carbamates";
var content_f36_57_37790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Neurologic effects of organophosphate and carbamate agents",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 341px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ACH: acetylcholine; Epi: epinephrine; NE: norepinephrine; NMJ: neuromuscular junction.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_57_37790=[""].join("\n");
var outline_f36_57_37790=null;
var title_f36_57_37791="Dx and rx exit site infection";
var content_f36_57_37791=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Flow chart for diagnosis and management of peritoneal catheter exit-site infections",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 599px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Keane, WF, Bailie, GR, Boeschoten, et al. Perit Dial Int 2000; 20:396.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_57_37791=[""].join("\n");
var outline_f36_57_37791=null;
